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Oral solid dosage forms: 
A solid dosage form is a drug delivery system that includes tablets, capsules, sachets 
and pills as well as a bulk or unit-dose powders and granules. Among the various 
dosage forms oral solid dosage forms have greater importance and occupy a prime role 
in the pharmaceutical market. Oral route of drug administration is widely acceptable 
and drugs administered orally as solid dosage form represents the preferred class of 
products. Over 90% of drugs formulated to produce systemic effects are produced as 
solid dosage forms. Because of this reason, whenever new chemical entity (NCE) has 
discovered, which shows a sufficient pharmacological action, first the pharmaceutical 
company asks whether the drug is successfully administered by oral route or not. The 
oral route of administration still continues to be the most preferred route due to its 
manifold advantages including: 
 Tablets and capsules represent unit dosage forms in which the accurate dose of 
drug to show sufficient pharmacological action can be administered. In case of 
liquid oral dosage forms such as syrups, suspensions, emulsions, solutions and 
elixirs the patient is asked to administer the medication of 5-30 ml. Such dosage 
measurements are typically error by factor ranging from 20-50 %, when the 
drug is self administered by patient. 
 Solid dosage forms are less expensive to shipping and less prone for the 
degradation when compared to liquid dosage forms.  
 Liquid dosage forms are less potable and require more space in pharmacist’s 
shelf. Drugs are generally less stable in liquid form. 
Tablets: 
Tablets are defined as solid preparations each containing a single dose of one or more 
active ingredients and obtained by compressing uniform volumes of particles. They are 
intended for oral administration, they can be swallowed whole, chewed, dispersed in 
water before being administered or retained in the mouth. Tablets are used mainly for 
systemic drug delivery but also for local drug action. For systemic use drug must be 
released from tablet that is dissolved in the fluids of mouth, stomach and intestine and 
then absorbed into systemic circulation by which it reaches its site of action. Tablets are 
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usually right, circular solid cylinders, the end surfaces of which are flat or convex and 
the edges of which may be beveled and may be coated. They may differ greatly in size 
and weight depending on the amount of drug substance present and the intended 
method of administration.  
Advantages of tablets 
• They are easy to administer. 
• They are in general the easiest and cheapest to package and ship of all oral 
dosage forms. 
• They lend themselves to certain special release profile products, such as enteric 
or delayed release products. 
• They are better suited to large scale production than other unit oral forms. 
• They have the best-combined properties of chemical, mechanical and 
microbiological stability of all the oral forms. 
Disadvantages of tablets: 
• Some drugs resist compression into dense compacts, owing to their amorphous 
nature or flocculent, low-density character. 
• Drugs with poor wetting, slow dissolution properties, intermediate to large 
dosages, optimum absorption high in the gastrointestinal tract, or any 
combination of these features may be difficult or impossible to formulate and 
manufacture as a tablet. 
• Bitter tasting drugs, drugs with objectionable odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation or a special type of 
coating which may increase the weight of the finished products [1,2]. 
 Types of tablets 
The main reasons behind formulation of different types of tablets are to create a 
delivery system that is relatively simple and inexpensive to manufacture, provide the 
dosage form that is convenient from patient’s perspective and utilize an approach that is 
unlikely to add complexity during regulatory approval process. To understand each 
dosage form, tablets here are classified by their route of administration and by the type 
of drug delivery system they represent within that route. 
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A. Tablets ingested orally:  
 1. Compressed tablet 
 2. Multiple compressed tablet  
 3. Repeat action tablet  
 4. Delayed release tablet, e.g. Enteric coated Bisacodyl tablet  
 5. Sugar coated tablet, e.g. Multivitamin tablet  
 6. Film coated tablet, e.g. Metronidazole tablet  
 7. Chewable tablet, e.g. Antacid tablet  
B. Tablets used in oral cavity:  
 1. Buccal tablet, e.g. Vitamin-C tablet  
 2. Sublingual tablet, e.g. Glyceryl tri nitate tablets 
 3. Troches or lozenges e.g. Vicks Menthol tablet 
 4. Dental cone  
C. Tablets administered by other route:  
 1. Implantation tablet  
 2. Vaginal tablet, e.g. Clotrimazole tablet  
D. Tablets used to prepare solution:  
 1. Effervescent tablet, e.g. Dispirin tablet (Aspirin)  
 2. Dispensing tablet, e.g. Enzyme tablet (Digiplex)  
 3. Hypodermic tablet  
 4. Tablet triturates e.g. Enzyme tablet (Digiplex)  
A. Tablets ingested orally:  
1. Compressed tablets: Standard uncoated tablets are manufactured by compression. 
The general methods are by wet granulation, dry granulation or direct compression, 
used for rapid disintegration and drug release. Both type of action – systemic effect and 
local effect.  
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2. Multiple Compressed tablets: For incompatible components these are formulated in 
two ways:  
a. Layered tablet- These are either two layered (for two components) or three layered 
(for three components) tablets.  
b. Compressed coated tablet- These are either tablet within a tablet or tablet within a 
tablet within a tablet. Tablet in this category are usually prepared for two reasons  
  1. To separate physically or chemically incompatible ingredients.  
  2. To produce repeat action or prolong action product.  
3. Repeat action tablet: Sugar coated or multiple compressed tablets are used for this 
purpose. The core tablet is usually coated with Shellac or an enteric polymer so that it 
will not release its drug in stomach but intestine.  
4. Delayed action and Enteric-coated tablet: This dosage form is intended to release 
the drug after some time delay or after the tablet has passed one part of the GIT into 
another. All Enteric coated tablets are type of Delayed action tablet but all Delayed 
action tablets are not Enteric or not intended to produce enteric action.  
5. Sugar coated tablet: Primary role of Sugar coating is to produce an elegant, glossy 
tablets. These are easy to swallow and widely utilized in preparing multivitamin and 
multivitamin mineral combination. Sugar coating doubled the tablet weight. Now 
polymers are used with sugar solution.  
6. Film coated tablet: One type of coated tablet in which drug is not required in 
coating. This is an attractive method within one or two hours. Polymers such as 
Hydroxypropylcellulose, Hydroxypropylmethyl cellulose, and colloidal dispersion of 
Ethylcellulose are commonly used. A 30% dispersion of Ethyl cellulose, is known as 
Aquacoat, is widely used in film coating. Advantage of film coated over sugar coated 
tablets is better mechanical strength and flexibility of the coating, little increase in 
tablet weight.  
7. Chewable tablet: These are intended to be chewed in the mouth before swallowing. 
Used for large tablet of antacid. Bitter or foul testing drugs are not suitable for this type 
tablet.  
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B. Tablets used in oral cavity:  
1. Buccal and sublingual tablet: These tablets are small, flat and are intended to be 
held between the cheek and teeth or in cheek pouch (buccal tablet) or below the tongue 
(sublingual tablet). Drugs used by this route are for quick systematic action. The tablets 
are designed not to be disintegrated but slowly dissolve.  
2. Troches and lozenges: These are used in the oral cavity to exert local effect in 
mouth and throat. They are commonly used to treat sore throat or to control coughing in 
common cold. They may contain local anesthetics, antiseptic, antibacterial agents, 
demulcents, astringent and anti tussive. These tablets are dissolving slowly over a 
period of 30 minutes.  
3. Dental cone: These tablets are designed to be placed in the empty socket remaining 
after tooth extraction. Main purpose is to prevent microbial growth in the socket or to 
reduce bleeding.  
C. Tablets administered by other route:  
1. Implantation tablets: These tablets are designed for substances implantation to 
provide prolonged drug effect from one month to a year; tablets are usually small, 
cylindrical not more than 8mm length. These methods require special surgical 
technique for implantation and discontinuation of therapy. Generally used for 
administration of growth hormone to food producing animal.  
2. Vaginal tablets: These are designed to undergo slow dissolution and drug release in 
vaginal cavity. Tablets are wide or pear shaped, used to produce antibacterial, antiseptic 
and astringent effects to treat vaginal infection.  
D. Tablets used to prepare solution: 
1. Effervescent tablets: Tablets are designed to produce a solution rapidly with the 
release of carbon dioxide. The tablets are prepared by compressing the active ingredient 
with mixture of organic acid such as Citric acid and Sodium bicarbonate.  
2. Dispersing tablets: Tablets are intended to be added to a given volume of water to 
produce a solution of a given drug concentration.  
3. Hypodermic tablets: These tablets are composed of one or more drugs with water-
soluble ingredients. Drug is added to sterile water to prepare sterile solution, which is 
injectable.  
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4. Tablet triturates: Usually these are made from moist materials using a triturate 
mold, which gives them the shape of cylinder. Generally these tablets consist of highly 
potent drugs [3]. 
Current technologies in oral drug delivery: 
Over the last three decades, many novel oral drug therapeutic systems have been 
invented along with the appreciable development of drug delivery technology. 
Although these advanced drug delivery systems are manufactured or fabricated in 
traditional pharmaceutical formulations, such as tablets, capsules, sachets, suspensions, 
emulsions, and solutions, they are superior to the conventional oral dosage forms in 
terms of their therapeutic efficacies, toxicities, and stabilities.  
Based on the desired therapeutic objectives, oral drug delivery system may be assorted 
into three categories:  
• Immediate-release preparations,  
• Controlled-release preparations and 
• Targeted- release preparations.  
Immediate-Release Preparations (IR): 
These preparations are primarily intended to achieve faster onset of action for drugs 
such as analgesics, antipyretics, and coronary vasodilators. Other advantages include 
enhanced oral bioavailability through transmucosal delivery and pregastric absorption, 
convenience in drug administration to dysphasic patients, especially the elderly and 
bedridden, and new business opportunities. 
Conventional immediate release (IR) formulations include fast disintegrating tablets 
and granules that use effervescent mixtures, such as sodium carbonate (or sodium 
bicarbonate) and citric acid (or tartaric acid), and superdisintegrants, such as sodium 
starch glycolate, croscarmellose sodium, and crospovidone. Current technologies in 
fast-dispersing dosage forms include modified tableting systems, floss or shear form 
technology, which employs application of centrifugal force and controlled temperature, 
and freeze-drying.  
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Controlled-Release Preparations (CR): 
The currently employed controlled release (CR) technologies for oral drug delivery are 
diffusion-controlled systems; solvent activated systems, and chemically controlled 
systems. Diffusion-controlled systems include monolithic and reservoir devices in 
which diffusion of the drug is the rate-limiting step, respectively, through a polymer 
matrix or a polymeric membrane. Solvent-activated systems may be either osmotically 
controlled or controlled by polymer swelling. Chemically controlled systems release 
drugs via polymeric degradation (surface or bulk matrix erosion) or cleavage of drug 
from a polymer chain. It is worth mentioning here that the so-called programmed-
release (‘‘tailored-release’’) profile of a final CR product is rarely the outcome of a 
single pharmaceutical principle. Depending on the specific physicochemical properties 
of the drug in question and desired therapeutic objectives, different formulation and CR 
principles may be proportionally combined within the same dosage form. This task 
appears to be simpler when realized in terms of appropriate selection of polymers and 
excipients that incorporate desired principles.  
Targeted-Release Preparations: 
Site-specific oral drug delivery requires spatial placement of a drug delivery device at a 
desired site within the GI tract. Although it is virtually possible to localize a device 
within each part of GI tract, the attainment of site-specific delivery in the oral cavity 
and the rectum is relatively easier than in the stomach and the small and large 
intestines. The latter requires consideration of both longitudinal and transverse aspects 
of GI constraints. 
 Method of Tablet Preparation: 
There are three general methods of tablet preparation. 
A. Direct compression method. 
B. Wet granulation method. 
C. Dry granulation method. 
A. Direct Compression method: In this method drug was accurately weighed and 
mixed thoroughly with excipients (which are directly compressible) by geometrical 
mixing method. The resultant mixture was compressed into tablet using tablet punching 
machine. 
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Commonly used directly compression diluents are: MCC (Microcrystalline cellulose 
(Avicel), Spray dried lactose, Starch - (Sta Rx 1500, Embdex, Celutab), Sugar 
 (Sugartab, Nutab), Dicalcium phosphate dihydrate (Di-Tab), Mannitol for chewable 
tablet. 
Steps involved in Direct Compression method:  
Raw material → Weighing → Screening → Mixing → Compression 
The ideal requirements of excipients used in direct compression and its advantages, 
limitations are as follows: 
Table 1: Ideal requirements& advantages & limitations of direct compression 
Ideal Requirement Advantages Limitations 
Flowability Cost effectiveness production Segregation 
Compressibility Better stability of drug Variation in functionality 
Dilution potential Faster dissolution Low dissolution potential 
Stability Simplified validation Poor compressibility of drug 
Controlled particle size Less microbial contamination Lubricant sensitivity 
 
Granulation: 
Granulation may be defined as a size enlargement process which converts small 
particles into physically stronger & larger agglomerates. Granulation method can be 
broadly classified into three types:  
 Wet granulation 
 Dry granulation 
 Dry Granulation incorporating bound moisture (MADG) 
Ideal characteristics of granules: 
The ideal characteristics of granules include uniformity, good flow, and compatibility. 
These are usually accomplished through creation of increased density, spherical shape, 
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narrow particle size distribution with sufficient fines to fill void spaces between 
granules, adequate moisture (between 1
Wet granulation: The concept of wet granulation is well
process for tablet formation, used to reduced bitterness of active drug with water 
insoluble materials. In wet granulation,
forms, is wetted with an aqueous composition of a granulating agent to cause the 
powdered material to agglomerates. This agglomerated product is subsequently dried 
and then milled to reduced size in suitable form. 
  
 
Fig. 1: Process principle for formation of agglomerates
Wet granulation is often carried out utilizing a high
granulation process is a rapid process which is susceptible for over
liquid amount added is critical and the optimal amount is affected by the properties of 
the raw materials. Power consumption of the impeller motor and the impeller torque 
have been applied to monitor the rheological properties of the wet mass during 
agglomeration and, thereby,
addition. However, these
additional process monitoring techniques would be valuable.
Important steps involved in wet granulation:
Raw materials → Weig
Drying → Screening → Mixing 
 
 Page 
-2%), and incorporation of binder, if necessary.
-known and conventional 
 the material to be granulated, usually in powder 
 
-shear mixer. The high
-wetting. Thus, the 
 have been used to determine the end-point of water 
 methods are affected by the equipment variables. Hence, 
 
 
hing → Screening → Wet massing → Sieving/Milling 
→ Compression. 
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1) Mixing of drug(s) and excipients. 
2) Preparation of binder solution. 
3) Mixing of binder solution with powder mixture to form wet mass. 
4) Coarse screening of wet mass using a suitable sieve (6-12 screens). 
5) Drying of moist granules. 
6) Screening of dry granules through a suitable sieve (14-20 screens). 
7) Mixing of screened granules with disintegrant, glidant and lubricant. 
Limitations of wet granulation: 
 The greatest disadvantage of wet granulation is its cost. It is an expensive 
process because of labor, time, equipment, energy and space requirements. 
 Loss of material during various stages of processing. 
 Stability may be a major concern for moisture sensitive or thermolabile drugs. 
 Multiple processing steps give complexity and make validation and control 
difficult. 
 An inherent limitation of wet granulation is that any incompatibility between   
formulation components is aggravated. 
Dry granulation: 
In Dry granulation process the powder mixture is compressed without the use of heat 
and solvent. It is the least desirable of all methods of granulation. The two basic 
procedures are to form a compact of material by compression and then to mill the 
compact to obtain a granules. Two methods are used for dry granulation. The more 
widely used method is Slugging, where the powder is pre-compressed and the resulting 
tablets or slugs are milled to yield the granules. The other method is to pre-compress 
the powder with pressure rolls using a machine such as Chilosonator. 
Steps in Dry granulation: 
Raw material → weighing → Screen → Mixing → Slugging → Milling → Screening 
→ Mixing → Compression 
 
Chapter 1 Introduction 
Department of Pharmaceutics Page 11 
 
 1) Milling of drugs and excipients 
2) Mixing of milled powders 
3) Compression into large, hard tablets to make slug 
4) Screening of Slugs 
5) Mixing with lubricant and disintegrating agent 
6) Tablet compression 
Two main dry granulation processes: 
Slugging process: 
Granulation by Slugging is the process of compressing dry powder of tablet 
formulation with tablet press having die cavity large enough in diameter to fill quickly. 
The accuracy or condition of slug is not too important. Only sufficient pressure to 
compact the powder into uniform slugs should be used. Once slugs are produced they 
are reduced to appropriate granule size for final compression by screening and milling. 
Roller compaction: 
The compaction of powder by means of pressure roll can also be accomplished by a 
machine called chilsonator. Unlike tablet machine, the chilsonator turns out a 
compacted mass in a steady continuous flow. The powder is fed down between the 
rollers from the hopper which contains a spiral auger to feed the powder into the 
compaction zone. Like slugs, the aggregates are screened or milled for production into 
granules. 
Procedure for Dry granulation method 
The excipients used for dry granulation are basically same as that of wet granulation or 
that of direct compression. With dry granulation it is often possible to compact the 
active ingredient with minor addition of lubricant and disintegrating agent. Fillers that 
are used in dry granulation include the following examples: Lactose, Dextrose, Sucrose, 
Microcrystalline cellulose, Calcium sulphate etc. 
Advantages:  
The main advantages of dry granulation or slugging are that it uses less equipment and 
space. It eliminates the need for binder solution, heavy mixing equipment and the costly 
and time consuming drying step as required in wet granulation. Slugging can be used 
for advantages in the following situations: 
I. For moisture sensitive material. 
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II. For heat sensitive material. 
III. For improved disintegration since powder particles are not bonded together by a 
binder. 
Disadvantages: 
1) It requires a specialized heavy duty tablet press to form slug. 
2) It does not permit uniform color distribution. 
3) Achieved with wet granulation where the dye can be incorporated into binder liquid. 
4) The process tends to create more dust than wet granulation, increasing the potential 
contamination [4,5,6]. 
Further, excipients are used also used in tablet manufacturing which are inert 
substances used as diluents or vehicles for a drug.  The screening of drug-excipient and 
excipient-excipient interactions should be carried out routinely in pre formulation 
studies [7]. 
Tablet Coating: 
The coating can have several functions. It can strengthen the tablet, control its release, 
improve its taste, color it, makes it easier to handle and package, and protect it from 
moisture. All drugs have their own characteristic, like some drugs are bitter in taste or 
have an unpleasant odor, some are sensitive to light or oxides, some are hygroscopic in 
nature, which can be altered by coating. Sugar coating was carried out initially which 
was now replaced by film coating. 
Tablet film coating is performed by two types, one is aqueous film coating generally 
water is used as a solvent) and non aqueous film coating (generally organic solvent are 
used). High quality aqueous film coating must be smooth, uniform and adhere 
satisfactorily to the tablet surface and ensure chemical stability of a drug, where as it 
need permission from the regulatory authority since organic solvents are used. 
Reasons for Tablet Coating: 
A number of reasons can be suggested: 
The core contains a material which has a bitter taste in the mouth or has an unpleasant 
odour, enhance the elegance, increase the mechanical integrity and stability. 
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The coated tablets can be packed on high-speed packaging machine. Coating reduces 
friction and increases packaging rate. 
Coating can modify the drug release profile, e.g., enteric coating, osmotic pump, 
pulsatile delivery [8,9]. 
Film Coating Materials: 
A film coating is a thin polymer-based coat applied to a solid dosage form such as a 
tablet. The thickness of such a coating is usually between 20-100 µm. Under close 
inspection the film structure can be seen to be relatively non- homogenous and quite 
distinct in appearance, from a film forming, from casting a polymer solution on a flat 
surface. 
Film coating formulations usually contain the following components: 
 1. Polymer 
 2. Plasticizer 
 3. Colourants / Opacifiers 
 4. Solvent / Vehicle. 
1. Polymer 
 Among the vast majority of the polymers used in film coating are cellulose derivatives 
or acrylic polymers and copolymers. 
Non-enteric polymers: 
Hypromellose, Hydroxy ethyl cellulose, Hydroxy ethyl methyl cellulose, Carboxy 
methyl cellulose sodium, Hydroxy propyl cellulose, Polyethylene glycol, Ethylcellulose 
Enteric polymers: 
Hypromellose phthalate, Polyvinyl acetate phthalate, Cellulose acetate phthalate 
Polymethacrylates, Shellac 
2. Plasticizers 
Plasticizers are simply relatively low molecular weight materials which have the 
capacity to alter the physical properties of the polymer to render it more useful in 
performing its function as a film coating material. Plasticizers are classified in three 
groups. Polyos type contains glycerol, propylene glycol, PEG (Polyethylene glycol). 
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Organic esters contain phthalate esters, dibutyl sebacetate, citrate esters, triacetin. 
Oils/glycerides contain castor oil, acetylated, monoglycerides, and fractionated coconut 
oil. 
3. Solvents/Vehicles 
The key function of a solvent system is to dissolve or disperse the polymers and other 
additives.  The major classes of solvents being used are 
 Water 
 Alcohols 
 Ketones 
 Esters 
 Chlorinated hydrocarbons 
Because of environmental and economic considerations, water is the solvent of choice; 
however organic coating is totally cannot be avoided. 
4. Colourants / Opaquants: 
 These materials are generally used as ingredients in film-coating formulae to 
contribute to the visual appeal of the product, but they also improve the product in other 
ways: 
 Identification of the product by the manufacturer and therefore act as an aid for 
existing GMP procedures. 
 Reinforcement of brand imaging and reduction in product counterfeiting. 
 Identification of the product by patients by using colourants and to prevent 
decomposition from exposure to light. 
Colourants are mainly classified in to three classes. Sunset yellow, Tartrazine, 
Erythrosine are examples of organic dyes and their lakes. Iron oxide yellow, red and 
black, Titanium dioxides, Talc are the examples of Inorganic colours. Anthrocyanins, 
Ribofloavine and Carmine are the examples of natural colours. 
Miscellaneous coating solution components: 
To provide a dosage form with a single characteristic, special materials may be 
incorporated into a solution. 
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Flavours and sweeteners are added to mask unpleasant odours or to develop the desired 
taste. For example, Aspartame, various fruit spirits (organic solvent), water soluble 
pineapple flavor (aqueous solvent) etc. 
Surfactants are supplementary to solubilize immiscible or insoluble ingredients in the 
coating. For example, Spans, Tweens etc. 
Antioxidants are incorporated to stabilize a dye system from oxidation and colour 
change. For example Oximes, Phenols etc. 
Antimicrobials are added to put off microbial growth in the aqueous coating 
composition which is prone for microbial growth. Ex. Alkyl iso thiazloinone, 
Carbamates, Benzothiazoles etc [10,11]. 
Coating Process: 
Film-coating of tablets is a multivariate process, with many different factors, such as 
coating equipment, coating liquid, and process parameters which affect the 
pharmaceutical quality of the final product. Coating liquid used  in the may affect the 
final quality of the tablets. Different film former have different chemical nature and 
different characteristics. Percentage Solid content generally affects the tablet surface 
and coating efficiency [12]. Process parameters such as  spray rate, atomizing air 
pressure, inlet air temperature and rotating speed of the fan also influences the coating. 
Optimization of the above said parameters results in the formation of a proper film, 
whereas improper spraying or altered air pressure, temperature and fan speed result in 
sticking of film, reduced tablet porosity, attrition and breakage [13,14,15]. 
 
Cancer: 
Cancer is a class of diseases characterized by out-of-control cell growth. There are over 
100 different types of cancer, and each is classified by the type of cell that is initially 
affected.  
Etiology of cancer: 
Normal cells in the body follow an orderly path of growth, division, and death. 
Programmed cell death is called apoptosis, and when this process breaks down, cancer 
begins to form. Unlike regular cells, cancer cells do not experience programmatic death 
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and instead continue to grow and divide. This leads to a mass of abnormal cells that 
grows out of control.  
 Classification: 
There are five broad groups that are used to classify cancer.  
1. Carcinomas are characterized by cells that cover internal and external parts of the 
body .such as lung, breast, and colon cancer.  
2. Sarcomas are characterized by cells that are located in bone, cartilage, fat, connective 
tissue, muscle, and other supportive tissues.  
3. Lymphomas are cancers that begin in the lymph nodes and immune system tissues.  
4. Leukemias are cancers that begin in the bone marrow and often accumulate in the 
bloodstream.  
5. Adenomas are cancers that arise in the thyroid, the pituitary gland, the adrenal gland, 
and other glandular tissues.  
Diagnosis: 
Physicians use information from symptoms and several other procedures to diagnose 
cancer. Imaging techniques such as X-rays, CT scans, MRI scans, PET scans, 
endoscopy and ultrasound scans are used regularly to detect where a tumor is located 
and what organs may be affected by it. Biopsies and various bio marker tests were also 
used to detect specific cancers, For example; cancerous prostate cells release a higher 
level of a chemical called PSA (prostate-specific antigen) into the bloodstream that can 
be detected by a blood test. 
 
Treatment: 
Cancer treatment depends on the type of cancer, the stage of the cancer (how much it 
has spread), age, health status, and additional personal characteristics. There is no 
single treatment for cancer, and patients often receive a combination of therapies and 
palliative care. Treatments usually fall into one of the following categories: surgery, 
radiation, chemotherapy, biological therapy, hormone therapy or gene therapy.  
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Renal cell carcinoma: 
Renal cell carcinoma (RCC, also known as Hypernephroma) is a cancer occurring in 
kidney that originates in the lining of the proximal convoluted tubule. RCC is the most 
common type of kidney cancer in adults, responsible for approximately 80% of cases. It 
is also known to be the most lethal of all the genitourinary tumors. Metastatic renal cell 
carcinoma presents a special challenge to oncologists, as about 70% of patients develop 
metastases during the course of their disease [16]. 
Prognosis of Renal cell carcinoma: 
The staging of renal cell carcinoma is the most important factor in predicting its 
prognosis. Staging can follow the TNM staging system, where the size and extent of the 
tumour (T), involvement of lymph nodes (N) and metastases (M) are noted. 
Stage I: Tumor of a diameter of 7 cm (approx. 23⁄4 inches) or smaller, and limited to 
the kidney. No lymph node involvement or metastases to distant organs. 
 Stage II: Tumor larger than 7.0 cm but still limited to the kidney. No lymph node 
involvement or metastases to distant organs.  
Stage III: Tumor of any size with involvement of a nearby lymph node but no 
metastases to distant organs. Tumor of this stage may be with or without spread to fatty 
tissue around the kidney, with or without spread into the large veins leading from the 
kidney to the heart. Tumor with spread to fatty tissue around the kidney and/or spread 
into the large veins leading from the kidney to the heart, but without spread to any 
lymph nodes or other organs.  
Stage IV: Tumor that has spread directly through the fatty tissue and the fascia 
ligament-like tissue that surrounds the kidney. Involvement of more than one lymph 
node near the kidney and or lymph node not near the kidney which are distant 
metastases, such as in the lungs, bone, or brain. 
Pathophysiology: 
The tissue of origin for renal cell carcinoma (RCC) is the proximal renal tubular 
epithelium. Renal cancer occurs in a sporadic (nonhereditary) and a hereditary form, 
and both forms are associated with structural alterations of the short arm of 
chromosome 3. Genetic studies of the families at high risk for developing renal cancer 
led to the cloning of genes whose alteration results in tumor formation. These genes are 
either tumor suppressors (VHL, TSC) or oncogenes (MET).  
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Fig. 2: Proliferation of tumours in Kidneys 
 
At least 4 hereditary syndromes associated with renal cell carcinoma are recognized:  
1. Von Hippel-Lindau (VHL) syndrome,  
2. Hereditary papillary renal carcinoma (HPRC),  
3. Familial renal oncocytoma (FRO) associated with Birt-Hogg-Dube syndrome 
(BHDS) 
4. Hereditary renal carcinoma (HRC).  
Von Hippel-Lindau syndrome 
It is an autosomal dominant syndrome that confers predisposition to a variety of 
neoplasms, including the following: 
a) Renal cell carcinoma with clear cell histologic features 
b) Pheochromocytoma 
c) Pancreatic cysts and islet cell tumors 
d) Endolymphatic sac tumors 
Renal cell carcinoma develops in nearly 40% of patients with von Hippel-Lindau 
disease and is a major cause of death among these patients. Deletions of 3p occur 
commonly in renal cell carcinoma associated with von Hippel-Lindau disease. The 
VHL gene is mutated in a high percentage of tumors and cell lines from patients with 
sporadic (nonhereditary) clear cell renal carcinoma. Several kindreds with familial clear 
cell carcinoma have a constitutional balanced translocation between 3p and either 
chromosome 6 or chromosome 8. Mutations of the VHL gene result in the 
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accumulation of hypoxia inducible factors (HIFs) that stimulate angiogenesis through 
vascular endothelial growth factor (VEGF) and its receptor (VEGFR). VEGF and 
VEGFR are important new therapeutic targets.  
Hereditary papillary renal carcinoma 
Hereditary papillary renal carcinoma is an inherited disorder with an autosomal 
dominant inheritance pattern; affected individuals develop bilateral, multifocal 
papillary renal carcinoma. Germline mutations in the tyrosine kinase domain of the 
MET gene have been identified.  
Familial renal oncocytoma and Birt-Hogg-Dube syndrome 
Individuals affected with familial renal oncocytoma can develop bilateral, multifocal 
oncocytoma or oncocytic neoplasms in the kidney. Birt-Hogg-Dube syndrome is a 
hereditary cutaneous syndrome. Patients with Birt-Hogg-Dube syndrome have a 
dominantly inherited predisposition to develop benign tumors of the hair follicle (ie, 
fibrofolliculomas), predominantly on the face, neck, and upper trunk, and these 
individuals are at risk of developing renal tumors, colonic polyps or tumors, and 
pulmonary cysts.  
Hereditary renal carcinoma 
Affected individuals with this inherited medical condition have an increased tendency 
to develop oncocytomas, benign kidney tumors that have a low malignant potential.  
Etiology: 
A number of environmental and genetic factors have been studied as possible causes for 
renal cell carcinoma (RCC), such as the following:  
Cigarette smoking doubles the risk of renal cell carcinoma and contributes to as many 
as one third of all cases. The risk appears to increase with the amount of cigarette 
smoking in a dose-dependent fashion.  
Obesity and hypertension are the associated risk factor, particularly in women; 
increasing body weight has a linear relationship with increasing risk. 
Phenacetin-containing analgesia taken in large amounts may be associated with 
increased incidence of renal cell carcinoma. 
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In renal transplant recipients, acquired renal cystic disease of the native kidney also 
predisposes to renal cell cancer. 
Von Hippel-Lindau disease is an inherited disease associated with renal cell carcinoma. 
 
Hepatocellular carcinoma 
 Hepatocellular carcinoma is cancer of the liver. 
Causes, incidence and risk factors 
Hepatocellular carcinoma accounts for most liver cancers. This type of cancer occurs 
more often in men than women. It is usually seen in people of age 50 years or older and 
is common in Africa and Asia than in North or South America and Europe. 
Hepatocellular carcinoma is not the same as metastatic liver cancer, which starts in 
another organ (such as the breast or colon) and spreads to the liver. 
In most cases, the cause of liver cancer is usually scarring of the liver (cirrhosis). 
Cirrhosis may be caused by: 
 Alcohol abuse (the most common cause in the United States) 
 Autoimmune diseases of the liver 
 Hepatitis B or C virus infection 
 Inflammation of the liver that is long-term (chronic) 
 Iron overload in the body (hemochromatosis) 
 Patients with hepatitis B or C are at risk for liver cancer, even if they have not 
developed cirrhosis. 
Symptoms 
 Abdominal pain or tenderness, especially in the upper-right part 
 Easy bruising or bleeding 
 Enlarged abdomen 
 Yellow skin or eyes (jaundice) 
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Signs and tests 
Physical examination may show an enlarged, tender liver. 
Tests include: 
 Abdominal enzymes (liver function tests) 
 Liver MRI 
 Serum alpha fetoprotein 
 CT scan 
 Abdominal ultrasound 
 Liver biopsy 
Complications 
 Gastrointestinal bleeding 
 Liver failure 
 Spread (metastasis) of the cancer 
Treatment 
Aggressive surgery or a liver transplant can successfully treat small or slow-growing 
tumors if they are diagnosed early. Radiation treatment and chemotherapy delivered 
straight into the liver with a catheter can help, but it will not cure the disease. However, 
many patients have liver cirrhosis or other liver diseases that make these treatments 
more difficult. 
Sorafenib: 
Sorafenib, a protein kinase inhibitor, approved by FDA in December 2005 for treatment 
of advanced renal cell carcinoma and hepato cellular carcinoma. 
Mechanism of action in Renal Cell Carcinoma (RCC): 
Sorafenib targets the VEGFRs and PRGFR, which are key elements in tumor 
progression and tumorogenesis. Sorafenib blocks the activation of RAS by the 
VEGF/PDGF receptors autophosphorylation and the resultant phosphorylation and 
transactivation to RAF and MEK/ERK. It thereby reduces tumor cell survival while 
impeding metastasis and tumor cell proliferation [17]. 
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down-regulation of Mcl-1 protein levels may take part in the proapoptotic effects of 
Sorafenib in human HCC [18]. 
 
 
 Sf-sorafenib 
 
Fig. 4: Diagrammatic representation of mechanism of action of sorafenib. 
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Reported work on present study: 
1. Sansonno et al., (2012) carried out a perspective, single center, placebo controlled, 
randomized, double blind study to evaluate the effectiveness of transarterial 
chemoembolization (TACE) combined with sorafenib in delaying time to progression 
(TTP) of intermediate stage HCC in patients with chronic hepatitis C virus infection. 
At the end of study sorafenib treatment was found to increase the TTP in patients [19].  
2. Kim et al., (2012) formulated sorafenib incorporated nanoparticles of dextran and 
poly (DL-lactide-co-glycolide) block copolymer for anti tumor drug delivery. This 
formulation was found to have a decreased drug release with increasing drug content 
and anti tumor activity as of sorafenib and thus can be suggested as vehicle for anti 
tumor drug targeting [20].  
3. Sacco et al., (2011) reported the effectiveness of the oral multikinase inhibitor 
sorafenib in Hepatocellular carcinoma (HCC), the fifth most common neoplasia in the 
world. It was also found that, as like other anti-angiogenic drugs employed in other 
tumour types, sorafenib also seldom induced the dimensional tumour shrinking 
usually observed with conventional cytotoxic drugs treatment of advanced HCC [21].  
4. Ling-lin et al., (2011) evaluated the effectiveness and toxicity of sorafenib for 
advanced hepatocellular carcinoma. Two Randomized Controlled Trials involving 
828 patients were taken for study. Compared with placebo, sorafenib significantly 
extended the overall survival and time to radiologic progression and improved the 
disease control rate. The main adverse effects were systemic, gastrointestinal, and 
dermatologic symptoms (grade 1 or 2 in severity), although the incidences were 
significantly higher in sorafenib groups than in control groups. Sorafenib was found 
to be effective and safe for the treatment of advanced hepatocellular carcinoma [22]. 
5. Yuxian Huang et al., (2011) reported that sorafenib and sunitinib are novel small 
molecule tyrosine kinase inhibitors with multiple targets on tumor cells, which have 
been demonstrated to be beneficial in the treatment of several carcinomas. Combining 
the usage of molecular targeted agents and adoptive cellular immunotherapy (ACI) 
against drug-resistant relapse nasopharyngeal carcinoma which had no standard 
therapeutic regimen was investigated by them in order to study whether synergistic 
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effects exist and related mechanisms. The results revealed for the first time that 
sorafenib and sunitinib could up-regulate NKG2DLs on tumor cells resulting in 
increased tumor cells cytotoxic sensitivity to NK cells, which suggested that 
combining usage of molecular targeted agents and ACI may result in great benefits in 
clinical practice for the therapy-resistant cases and drug-resistant relapse [23]. 
6. Steven Simoens (2011) conducted a literature review of the dosage and treatment 
duration; safety, tolerability and effectiveness; costs and cost-effectiveness of 
sorafenib in routine clinical care. The most common drug-related adverse events were 
hand-foot skin reaction, rash, hypertension, and fatigue. Although treatment with 
sorafenib led to fewer dose reductions, it was also associated with shorter treatment 
duration, less time to pro-gression and a shorter survival time as compared to 
sunitinib. Monthly health care costs were lower with sorafenib as compared to 
sunitinib. A post-marketing surveillance study showed that patients rated the 
tolerability and effectiveness of sorafenib as very good, good or sufficient [24]. 
7. Anton Smith (2011) formulated film coated tablets of secnidazole by wet granulation 
method and granules are compressed for tablets and they are coated with polymers by 
using hydroxypropyl methyl cellulose and advatia prime pink. The resulted tablets 
were evaluated for different parameter and concluded that the coating has not shown 
any effect on the dissolution of the drug [25].  
8. Takafumi Kennoki et al., (2011) investigated the safety and feasibility of sorafenib in 
patients with end-stage renal disease undergoing hemodialysis by examining the 
influence of pharmacokinetic parameters to their benefit and also the occurrence of 
drug-related adverse events of sorafenib. Treatment with sorafenib in patients with 
metastatic renal cell carcinoma undergoing hemodialysis appears to be feasible, with 
higher incidence of serious adverse events without any change in clinical efficacy [26]. 
9. Hong et al., (2011) reported the use of sorafenib in patients with advanced renal cell 
carcinoma who have failed prior cytokine-based therapy are considered unsuitable for 
such therapy. To find the effectiveness of the drug in real-life practice, an open-label 
study was observed in patients with stable disease for eight weeks. It was found that 
the most common drug-related adverse events were hand-foot skin reaction, rash, 
hypertension, and fatigue. Although treatment with sorafenib led to fewer dose 
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reductions, it was also associated with shorter treatment duration, less time to 
progression and a shorter survival time as compared to sunitinib [27]. 
10. Saby George et al., (2011) reported that the first case report of the use of sorafenib 
and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte 
colony-stimulating factor (G-CSF). This entity is clinically rare and has a poor 
outcome. A 78-year-old Japanese man presented with macrohematuria, left flank 
pain, and a palpable mass. Laboratory data showed marked leukocytosis with 
increased serum and urinary G-CSF. The histopathological diagnosis was unclassified 
RCC. New combination therapy with sorafenib and S-1 exerted a therapeutic effect 
and apparently decreased serum and urinary G-CSF levels, although the patient died 
of gastrointestinal perforation. The use of combined sorafenib and S-1 was suggested 
to a worthy consideration in the treatment of RCC producing G-CSF [28].  
11.  Wei et al., (2011) investigated the safety and efficacy of sorafenib in combination 
with chemotherapy for the treatment of FLT3 positive acute myeloid leukemia 
(AML), to highlight the impact of FLT3 mutations and targeting therapy on response 
of AML. The clinical and laboratory features and the treatment response, especially 
the safety profile of sorafenib in an acute monocytic leukemia patient with FLT-ITD 
were reported. The patient achieved clinical and molecular CR after sorafenib was 
added to the second course of combination chemotherapy. The side effects of 
sorafenib were mild and tolerable. The patient responded well to the combination of 
sorafenib and standard chemotherapy of AML without significant adverse effects [29].  
12. Wang et al., (2011) formulated nanoparticulate-nanomatrix formulation of sorafenib 
to increase its absorption using porous material sylysia-350 and polymer eudragit. It 
was found in  that study  there was a 13-33 times increase in bioavailability in the 
nano matrix formulation using sylysia nanomatrix and 16.8 to 40.8% in eudragit nano 
particles [30].  
13. Duman et al., (2011) reported the efficacy of vit-E treatment in hand foot skin 
syndrome (HFS) associated with sorafenib treatment. It was found that vit-E had a 
marked effect on HFS and it decreased the skin lesion without any dose modification 
of sorafenib [31].  
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14. Li, Huang et al., (2010) reported the more evidence sources to the standard treatment 
for patients with advanced hepatocellular carcinoma. Parameters such as patient’s 
time to progression (TTP) and overall survival (OS) after patients receiving 
Transcatheter Arterial Chemo Embolization (TACE) combined with sorafenib as a 
treatment of advanced hepatocellular carcinoma (HCC), the healing effect 
embolization combined with anti-angiogenic activity in hepatocellular carcinoma 
were analysed. The study concluded, TACE combined with sorafenib treatment may 
give patients with advanced hepatocellular carcinoma a longer longevity and keep the 
disease in a steady state and can be considered in the treatments to patients with 
advanced hepatocellular carcinoma [32]. 
15. Ikeda et al., (2010) reviewed the efficacy of sorafenib compared to placebo in hepato 
cellular carcinoma. Sorafenib demonstrated to yield a significantly favorable disease 
control rate and also favorable prolongation of progression-free survival and overall 
survival in patients with advanced hepatocellular carcinoma. Further, use of sorafenib 
as adjuvant therapy after local treatment, including surgical resection, local ablative 
therapy and transcatheter arterial chemoembolization for hepatocellular carcinoma 
were also discussed [33]. 
16. Bengala et al., (2010) reported that use of sorafenib in advanced biliary tract 
carcinoma which has a very poor prognosis, with chemotherapy being the mainstay of 
treatment. Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-β, B-Raf, and 
C-Raf, has shown to be active in preclinical models of cholangiocarcinoma [34].  
17. Benjamin Hagopian, et al., (2010) reported case report details of a patient with an 
unusually severe and painful skin reaction, in spite there are multiple reports on 
sorafenib-induced hand foot skin reaction. In this case report, the bullous skin 
reaction, debilitating hand pain, and absence of foot involvement were reported for 
the first time [35].  
18.  Kamada et al., (2010) reported that targeted therapies used in the treatment of 
metastatic renal cell carcinoma (RCC) are known to have the potential for 
cardiotoxicity and should be used with caution in patients with cardiac co morbidities. 
A retrospective review identified two RCC cases treated with sorafenib in the context 
of pre existing cardiomyopathy. Sorafenib therapy resulted in disease stabilization of 
progressing RCC for both cases, without worsening the cardiac ejection fraction [36].  
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19. Degen et al., (2010) evaluated the effect on multiple cutaneous side effects during 
sorafenib therapy and possible association of epithelial skin cancer growth. The 
authors reported 2 patients who developed a basal cell carcinoma (BCC) while treated 
with sorafenib. It was found that, after termination of sorafenib treatment, no new 
BCCs or other epithelial skin cancers occurred [37].  
20. Mila Petrova et al., (2010) reported that medullary thyroid cancer (MTC) is a rare 
and only surgically treatable disease with early development of metastases and bad 
prognosis. Due to the lack of efficient systemic treatment, new strategies were 
adopted, such as the use of tyrosine multikinase inhibitors like sorafenib and was 
effective in patient with metastatic MTC treated for two months [38]. 
21. Hari koul et al., (2009) reviewed the dose-dependent inhibition of cell proliferation 
and induction of apoptosis seen with sorafenib in human hepatocellular carcinoma 
cells lines. Sorafenib demonstrated dose-dependent anti tumour activity in a murine 
xenograft model of human hepatocellular carcinoma. The bi-aryl urea sorafenib (oral 
multikinase inhibitor) was found to act by inhibiting cell surface tyrosine kinase 
receptors (e.g. vascular endothelial growth factor receptors and platelet-derived 
growth factor receptor-beta) and downstream intracellular serine/threonine kinases 
(e.g. Raf-1, wild-type B-Raf and mutant B-Raf); these kinases are involved in tumour 
cell proliferation and tumour angiogenesis [39].  
22. Lettieri et al., (2009) performed a study to assess whether the change of formulation 
alters the bioavailability of sorafenib. Some patients who are unable to swallow 
tablets have suspended sorafenib tablets in a liquid for ease of administration. The 
pharmacokinetics of sorafenib, when administered as a liquid suspension of tablets in 
water was found to be similar to the pharmacokinetics of tablets swallowed as whole. 
Further, the use of sorafenib (multikinase inhibitor currently approved by the FDA) 
for the treatment of advanced renal-cell carcinoma (RCC) and unresectable 
hepatocellular carcinoma (HCC), and by the EMEA for the treatment of HCC and 
advanced RCC were also discussed [40].  
23. Jun-Yan Liu, et al., (2009) reported that sorafenib has epoxide hydrolase (she) 
inhibitory activity which contributes to its effect profile in vivo the advent of multi-
kinase inhibitors targeting the VEGF-receptor which revolutionized the treatment of 
highly angiogenic malignances such as renal cell carcinoma. It was also found that, 
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several such inhibitors are commercially available, and they each possess diverse 
specific beneficial and adverse effect profiles. Structural examination of sorafenib, 
hypothesized that this compound would possess inhibitory effects on the soluble 
epoxide hydrolase (sEH), an enzyme with pleiotropic effects on inflammation and 
vascular disease [41]. 
24. Robert Justice et al., (2009) exhibited the report of U.S. Food and Drug 
Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a 
new small-molecule, oral, multi-kinase inhibitor for the treatment of patients with 
advanced renal cell carcinoma (RCC). FDA reviewed the phase 3 protocol under the 
Special Protocol Assessment mechanism, following new drug application submission, 
FDA independently analyzed the results of two studies in advanced RCC: a large, 
randomized, double-blinded, phase 3 international trial of single-agent sorafenib and 
a supportive phase 2 study [42].  
25. Wong Michael et al., (2009) reported that cardiotoxicity is an emerging concern with 
a new class of drugs known as targeted agents, which include trastuzumab and 
sunitinib. Sunitinib is a small molecule that inhibits multiple tyrosine kinase receptors 
(approved by the United States Food and Drug Administration in 2006) for the 
treatment of clear cell metastatic renal cell carcinoma and advanced gastrointestinal 
stromal tumors. It was observed that sunitinib was found to cause heart failure, thus 
sorafenib, another tyrosine kinase inhibitor, was started with the aim of continuing 
her previous response to sunitinib. After 7 months of sorafenib therapy, the patient 
had no evidence of heart failure and concluded the use of sorafenib after sunitinib-
induced heart failure appears to be safe and effective, which suggests that 
cardiotoxicity, is not a general class effect of the tyrosine kinase inhibitors [43]. 
26. Sebastien J Hotte et al., (2008) reported a case of adult clear-cell RCC with extensive 
rhabdoid features treated with the tyrosine kinase inhibitor sorafenib. In this report, 
Sorafenib appeared to confer prolonged disease stabilization and warrants further 
study in other rare subtypes of RCC [44]. 
27. Ambrosini et al., (2008) reported the possible mechanism my which sorafenib act. 
When tumor cells were treated with sorafenib, it found to inhibit phospho-MEK, 
phospho-ERK and cell cycle arrest [45]. 
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28. William L. Dahut et al., (2008) reported the use of sorafenib in androgen-
independent prostate cancer (AIPC). Interpretation of this study is complicated by 
discordant radiographic and prostate-specific antigen (PSA) responses [46].  
29. Anil Kapoor et al., (2008) reported that renal cell carcinoma (RCC) with rhabdoid 
features is an uncommon and highly aggressive malignancy. A review of the 
literature confirms that adult rhabdoid RCC is a rare but aggressive tumour with a 
distinctly poor prognosis and in their patient, sorafenib appeared to confer prolonged 
disease stabilization and warrants further study in this and other subtypes of RCC [47]. 
30. Liliana Moreno-Vinasco et al., (2008) investigated that pulmonary hypertension 
(PH) and cancer pathology share growth factor- and MAPK stress-mediated signaling 
pathways resulting in endothelial and smooth muscle cell dysfunction and 
angioproliferative vasculopathy. In this study, they reported that, sorafenib, an 
antineoplastic agent and inhibitor of multiple kinases important in angiogenesis 
[VEGF receptor (VEGFR)-1–3, PDGF receptor (PDGFR)-β, Raf-1 kinase] as a 
potential PH therapy [48].  
31. Gudena, et al., (2008) reported that malignant schwannomas or malignant peripheral 
nerve sheath tumors (MPNST) represent approximately 10% of all soft tissue 
sarcomas. Case study of a metastatic disease from chest wall MPNST is very rare and 
the response to tyrosine kinase inhibitor (TKI) sorafenib in a 42 year female patient 
with metastatic MPNST was reviewed and it was reported. MPNST show high levels 
of Ras activity and hence these tumors are promising targets for TKIs studies [49]. 
33. Guan et al., (2008) reported that sorafenib is a novel oral bis-aryl urea compound that 
has proven survival benefit in patients with advanced hepatocellular carcinoma 
(HCC), for which several therapies are currently available with unsatisfactory results. 
Sorafenib is the first compound to demonstrate a significant effect on survival in 
HCC. With the approval of sorafenib being given the significance of a milestone, 
systemic treatment of HCC is no longer regarded as ineffective [50].  
34. Honary et al., (2007) has studied the effect of film coating solution containing 
different grades of HPMC (E5, E15 and E50) with and without polyethylene glycol 
(with various molecular weights), for the characterization of pharmaceutical products 
[51]
.  
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35. Flaherty et al., (2007) reported that sorafenib is an orally available inhibitor of 
vascular endothelial growth factor receptors, platelet-derived growth factor receptor-
β, and RAF kinases. A dose of 400 mg twice daily administered continuously was 
selected for phase 2 testing, although 600 mg twice daily formally met criteria for a 
maximum tolerated dose. A phase 3 trial with sorafenib confirmed a benefit of 
therapy across the vast majority of patients treated with sorafenib as opposed to 
placebo [52].  
36. Gloria Gamat et al., (2007) reported the large scale multinational trial, conducted by 
researchers from the Mount Sinai School of Medicine in New York and Hospital 
Clinic of Barcelona (Spain), sorafenib pill was found to work on tumors within the 
liver and those that have already spread in other parts of the body [53].  
37. Kane Rc et al., (2006). This report describes the U.S. Food and Drug Administration 
(FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-
molecule, oral, multi-kinase inhibitor for the treatment of patients with advanced 
renal cell carcinoma (RCC). The recommended dose is 400 mg (two 200-mg tablets) 
twice daily taken either 1 h before or 2 h after meals. Adverse events were 
accommodated by temporary dose interruptions or reductions [54]. 
38. Care Hughes et al., (2006) summarized the pharmacology, development, and clinical 
application of sorafenib, a specific tyrosine kinase and vascular growth factor 
inhibitor, for the treatment of renal cell carcinoma. Sorafenib is a novel oral tyrosine 
kinase inhibitor effective in the treatment of RCC [55]. 
39. Preetha., (2000) has studied the effect of mode of incorporation of super disintegrants 
such as crosarmellose sodium, Sodium starch glycolate and crospovidone on 
dissolution.The results indicated that the formulation containing Croscarmellose 
sodium has shown best release profile than the other super disintegrants due to the 
rapid swelling action of the polymer [56].  
40. Tang (2000) has studied the effect of film coating on the release of chloramphenicol 
maleate tablets and was observed that film coating of aqueous solution of hydroxy 
propyl methyl celluolose improves the dissolution profile. It was found that the 
increased dissolution rate is due to the easy penetration of solvent in to the HPMC, 
which helps in wetting of core tablet [57]. 
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The aim of present work is to develop a  pharmaceutically stable, effective and quality improved 
formulation containing Sorafenib tosylate as an active moiety. 
To achieve this formulation, various prototype formulation trials were taken and evaluated with 
respect to various quality control such as dissolution. The formula will be finalized by comparing 
the invitro dissolution profile with the reference product. 
Formulation of potent drug molecules as a dosage form still draws continuous interest and 
challenges against optimization towards pharmacokinetic parameters like absorption, onset of 
action, bio-availability and also economic factors. Sorafenib tosylate, antineoplastic agent, is a 
multikinase inhibitor used to treat Renal Cell Carcinoma (RCC). RCC is a form of kidney cancer
which accounts for 90-95% of tumours arising from the kidney and represents approximately 2% 
of all adult malignant tumours. Treatment of RCC with sorafenib tosylate increases the overall 
surveillance of the patient up to 40%. 
The main objective of the present study is to: 
1.  To formulate and evaluate Sorafenib tosylate film coated tablets. 
2. Improve the Bioavailability of the drug:  Sorafenib tosylate bioavailability is 29-49%. By the 
use of disintegrants, the bioavailability of the drug can be enhanced. 
3. To determine the best fit dissolution profile for the dosage form. 
4. To study the release profile of the dosage form and to compare their drug release profile with 
the reference product. 
5. To provide a low cost generic version of the reference product (Nexavar). 
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The present proposed research work was planned as per the following experimental protocol 
 Literature survey: 
Literature survey on the various works carried out on this topic is reviewed. 
 Procurement of chemicals: 
Procurement of drug and other ingredients required for the study. 
 Preformulation: 
a. Physical observation 
b. Bulk density 
c. Tapped density 
d. Hausner‘s Ratio 
e. Car‘s index 
f. Particle size distribution 
g. Solubility 
h. Compatibility studies of drug with various excipients 
 Formulation: 
 Tablets will be prepared by compression method using various grades of excipients in 
different ratios. 
 Film coating tablets:  
Film coating will be done to prepare tablets by using film coating polymer like HPMC, 
Advantia Prime Pink. 
 Evaluation of tablets: 
Tablet appearance 
 Thickness 
Hardness 
Disintegration test  
% Friability 
Weight variation 
Content uniformity 
in vitro dissolution testing. 
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Drug profile 
Sorafenib tosylate [58] is an orally active, antineoplastic agent which acts as a protein kinase 
inhibitor. 
 Structural formula: 
 
CAS number  : 284461-73-0 
Molecular formula : C21H16ClF3N4O3 
Molecular Weight : 464.825 
IUPAC name  : 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino] 
             phenoxy]-N-methyl-pyridine-2-carboxamide 
Description  : White to pale yellow in colour 
Solubility  : Soluble in PEG 
           Slightly soluble in ethanol 
           Insoluble in water 
Category  : Multikinase inhibitor 
Melting Point  : 187.6 
Taste & Odour : Tasteless, Odourless 
Absorption   : Absorbed through GI tract 
Protein binding  : 99.5% 
Half life   : 25- 48 hrs 
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Clearance   : 1280 ±67 mL/min. 
logP    : 4.12 and 4.34 
pKa    :13.99 
Dose    : 200 mg daily in divided doses 
Cmax     : 12.5 µmol/L 
Tmax    : 4 hrs 
Bioavailability : 25- 49% 
Clinical pharmacology: 
Mechanism of action: Sorafenib is a protein kinase inhibitor that decreases tumour cell 
proliferation. It has shown to inhibit multiple intracellular (CRAF,BRAF) and cell surface 
kinases like KIT, FLT, RET, VEGFR, PDGFR. Several of these kinases are involved in tumour 
cell signaling, angiogenesis and apoptosis. Sorafenib inhibit tumour growth and angiogenesis of 
human renal cell carcinoma [59]. 
Pharmacokinetics: 
Absorption: 
Following oral administration, sorafenib reaches peak plasma levels in approximately 3 hours. 
When given with a moderate-fat meal (30% fat; 700 calories), bioavailability was similar to that 
in the fasted state. With a high-fat meal (50% fat; 900 calories), sorafenib bioavailability was 
reduced by 29% compared to administration in the fasted state. It is recommended that be 
sorafenib administered without food. Mean Cmax and AUC increased less than proportionally 
beyond doses of 400 mg administered orally twice daily. 
Distribution: In vitro binding of sorafenib to human plasma proteins is 99.5%. Human serum 
albumin, α-globulin and the low density lipoprotein are the main binding proteins. Sorafenib was 
equally distributed between plasma and blood cells. The binding of sorafenib to the plasma is  
pH dependent. The fraction unbound decreased to 0.165% at pH7.99 and increased to 1.80% at 
acidic pH 6.78.  
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Metabolism: Sorafenib is metabolized primarily in the liver, undergoing oxidative metabolism, 
mediated by CYP3A4, as well as glucuronidation mediated by UGT1A9. Sorafenib accounts for 
approximately 70-85% of the circulating analytes in plasma at steady-state. Eight metabolites of 
sorafenib have been identified, of which five have been detected in plasma. The main circulating 
metabolite of sorafenib in plasma, the pyridine N -oxide, shows in vitro potency similar to that of 
sorafenib. This metabolite comprises approximately 9-16% of circulating analytes at steady-
state.                             
 Excretion: Following oral administration of a 100 mg dose of a solution of Sorafenib, 96% of 
the dose was recovered within 14 days, with 77% of the dose excreted in feces, and 19% of the 
dose excreted in urine as glucuronidated metabolites. Unchanged sorafenib, accounting for 51% 
of the dose, was found in feces but not in urine. 
Drug interactions: Sorafenib tosylate has found to have drug interactions with carboplatin, 
paclitaxel, docetaxel, doxorubicin, fluorouracil and neomycin. 
Dosing and administration: 400 mg (2 tablets) orally twice daily without food.                   
Treatment interruption and/or dose reduction may be needed to manage suspected adverse drug 
reactions. Dose may be reduced to 400 mg once daily or to 400 mg every other day. 
 
Excipient Profile 
MICROCYSTALLINE CELLULOSE [60] 
Nonproprietary Names: 
BP: Microcrystalline cellulose 
IP: Microcrystalline cellulose 
PhEur: Cellulosum microcristallinum 
USPNF: Microcrystalline cellulose 
Synonyms: 
Avicel PH, Celex, cellulose gel, Celphere, Ceolus KG, crystalline cellulose, E460, Emcocel, 
Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur. 
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Description: 
Microcrystalline cellulose is purified, partially depolymerized
odorless, tasteless, crystalline powder composed of porous particles. It is commercially available 
in different particle sizes and moisture grades that have different properties and applications.
Empirical Formula and Molecular Weight: 
Molecular structure: 
Functional Category: 
Adsorbent; Suspending agent; as a Diluent in tablets and capsules; tablet disintegrant.
Applications in Pharmaceutical Formulation or Technology:
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluent in oral 
tablet and capsule formulations where it is used in both wet granulation and direct
processes. In addition to its use as a binder/diluent, microcrystalline cellu
lubricant and disintegrates properties that make it useful in tableting. Microcrystalline cellulose is 
also used in cosmetics and food products 
hygroscopic material. The bulk materia
place. 
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l should be stored in a well-closed container in a cool, dry 
 
Page 37 
 
 
 
-compression 
Chapter 5                                                            Drug and excipient profile 
Department of Pharmaceutics  Page 38 
 
CROSCARMELLOSE SODIUM [63,64] 
Nonproprietary Name: Croscarmellose sodium 
Synonyms: Ac-di-sol; carmellosum natricum conexum; Crosslinked carboxymethylcellulose 
sodium; Explocel:modified cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; 
Vivasol. 
Chemical Name: Cellulose, carboxy methyl ether, sodium salt. 
 
Functional Category: Tablet and capsule disintegrant. 
Description: Croscarmellose sodium occurs as an odorless, white or grayish-white powder. 
Solubility: Insoluble in water, although Croscarmellose sodium rapidly swells to 4-8 times its 
original volume on contact with water. It is practically insoluble in acetone, ethanol and toluene. 
Stability and Storage Conditions: Croscarmellose sodium is a stable though hygroscopic 
material. A model tablet formulation prepared by direct compression, with croscarmellose 
sodium as a disintegrant showed no significant difference in drug dissolution after storage at 
3000C for 14 months. Croscarmellose sodium should be stored in a well closed container in a 
cool, dry place. 
Incompatibilities: The efficacy of Croscarmellose sodium, may be slightly reduced in tablet 
formulations prepared by either the wet-granulation or direct compression process that contain 
hygroscopic excipients such as sorbitol. Croscarmellose Sodium is not compatible with strong 
acids or with soluble salts of iron and metals such as aluminum, mercury and zinc. 
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Applications: Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets and granules. In tablet formulations, croscarmellose sodium 
may be used in both direct-compression and wet-granulation processes. When used in wet 
granulations, the croscarmellose sodium should be added in both the wet and dry stages of the 
process (intra and extra- granularly) so that the wicking and swelling ability of the disintegrant is 
best utilized. Croscarmellose sodium at concentrations up to 5% w/w may be used as tablet 
disintegrant, although normally 2% w/w is used in tablets prepared by direct compression and 
3%w/w in tablet prepared by wet granulation process. 
Related Substances: Carboxy methyl cellulose calcium: Carboxy methyl cellulose sodium. 
 
 
CROSPOVIDONE [65] 
 
Nonproprietary Name: Crospovidone. 
Synonyms: Crospovidonum; Polyplasdone XL; Polyvinylpolypyrrolidone. 
Chemical Name: 1-Ethenyl-2-pyrrolidinone homopolymer 
              
Empirical Formula: (C6H9NO) n 
Molecular Weight: >1 000 000 
Functional Category: Tablet disintegrant 
Description: Crospovidone is a white to creamy-white, finely divided, free flowing, practically 
tasteless, odorless or nearly odorless, hygroscopic powder. 
Solubility: Practically insoluble in water and most common organic solvents. 
Stability and Storage Conditions: Since crospovidone is hygroscopic, it should be stored in an 
airtight container in a cool, dry place. 
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Incompatibilities: Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular adducts with 
some materials. 
Applications: Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at 
2-5 % concentration in tablets prepared by direct compression or wet- and dry-granulation 
methods. It can also be used as a solubility enhancer. 
Related Substances: povidone. 
  
SODIUM STARCH GLYCOLATE [66] 
Nonproprietary Name:  
Synonyms: Carboxymethyl starch, sodium salt; carboxymethylamylumnatricum; Explosol; 
Explotab; Glycolys; Primojel; starch carboxymethyl ether, sodium salt; Tablo; Vivastar P 
Chemical Name: Sodium carboxymethyl starch. 
 
Functional Category: Tablet and capsule disintegrant. 
Description: It is a white or almost white free-flowing very hygroscopic powder. The PhEur 6.0 
states that when examined under a microscope it is seen to consist of: granules irregularly 
shaped, ovoid or pear-shaped, 30–100 mm in size, or rounded,10–35 mm in size; compound 
granules consisting of 2–4 components occur occasionally; the granules have an eccentric hilum 
and clearly visible concentric striations. The granules show considerable swelling in contact with 
water [67,68]. 
Solubility: Practically insoluble in water and insoluble in most organic solvents. 
Stability and Storage Conditions: Tablets prepared with sodium starch glycolate have good 
storage properties. Sodium starch glycolate is stable although very hygroscopic, and should be 
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stored in a well-closed container in order to protect it from wide variations of humidity and 
temperature, which may cause caking. The physical properties of sodium starch glycolate remain 
changed for up to 3 years if it is stored at moderate temperatures and humidity. 
 
Incompatibilities: Sodium starch glycolate is incompatible with ascorbic acid.  
 
Applications: It is widely used in oral pharmaceuticals as a disintegrant in tablets and capsule 
formulations. It is recommended to use in tablets prepared by either direct-compression or wet 
granulation processes [69]. 
 
HYDROXYPROPYL METHYL CELLULOSE (HPMC) [70] 
Non-proprietary names: 
IP: Hydroxypropylmethylcellulose 
BP: Hypromellose  
Ph Eur: Methylhydroxypropylcellulosum 
USP: Hypromellose 
Chemical Name: Cellulose, 2-hydroxypropyl methyl ether 
Synonyms: Methyl Hydroxy Propyl cellulose; Propylene Glycol ether of methylcellulose; 
CulminalHPMC. 
Structural Formula: 
OR
CH2OR
O
OO
O
O
OR
OR
OR
CH2OR
Where R is H, CH3 or CH3-CH(OH)-CH2
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Physical and chemical properties 
Molecular weight   : 10,000 - 15,00,000 
Color        : White to creamy-white 
Nature        : Fibrous or granular powder 
Odor       : Odorless 
Taste       : Tasteless 
Density       : 0.3-1.3 g/mL 
Specific gravity    : 1.26 
Solubility       : Soluble in cold water, practically insoluble in chloroform, ethanol (95%) and 
ether but soluble in mixture of ethanol and dichloromethane. 
Viscosity       : HPMC-K4M-3,000-5600mPas 
K15M: 12,000-21,000mPas 
K100M: 80,000-1, 20,000mPas 
Melting point     : Browns at 190-200 °C, chars at 225-230 °C, glass transition      temperature is 
170-180°C. 
Functional Category: 
Used as Coating agent, film-forming, rate-controlling polymer for sustained release, stabilizing 
agent, suspending agent, tablet binder, viscosity-increasing agent. 
Applications:  
HPMC is widely used in oral and topical pharmaceutical formulation. In oral products HPMC is 
primarily used as tablet binder. Concentration between 2-5% w/w may be used as a binder in 
either wet or dry granulation process. Concentration of 0.45-1% w/w may be added as a 
thickening agent to vehicle for eye drops and artificial tear solution. HPMC is used as an 
adhesive in plastic bandage and as a wetting agent for hard contact lenses. It is widely used in 
cosmetics and food products. In addition, HPMC is used as an emulsifier, suspending agent and 
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stabilizing agent in topical gels and ointments. As a protective colloid, it can prevent droplets 
and particle from coalescing or agglomerating thus, inhibiting the formation of sediments [71]. 
Stability and storage 
It is stable although it is slightly hygroscopic. The bulk material should be stored in an airtight 
container in a cool and dry place. Increased in temperature reduces the viscosity of the solution. 
Safety: It is generally regarded as a non-toxic and non-irritant material, so it is widely used in 
many oral and topical pharmaceutical formulations. Excessive consumption of HPMC may have 
laxative effect. 
 
SODIUM LAURYL SULPHATE [72] 
Synonyms: Dodecyl sodium sulphate; Elfan 240  
                      
Empirical Formula: C12H25NaO4S 
Molecular Weight: 288.37 
Solubility: Freely soluble in water forming opalescent solution, practically insoluble in 
chloroform, ether. 
Functional Category: Anionic surfactant. 
Description: White cream to pale yellow coloured crystals, bitter in taste. 
Incompatibilities: Incompatible with strong oxidizing agents. 
Applications: SDS is mainly used in detergents for laundry and many cleaning applications. 
SDS is a highly effective surfactant and is used in any task requiring the removal of oily stains 
and residues. 
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MAGNESIUM STEARATE [73,74] 
Nonproprietary Names: 
BP: Magnesium stearate 
IP: Magnesium stearate 
PhEur: Magnesii stearas 
USPNF: Magnesium stearate 
Synonyms: Magnesium octadecanoate; octadecanoic acid; magnesium salt; stearic acid. 
Chemical Name : Octadecanoic acid magnesium salt 
 
Functional Category : Tablet and capsule lubricant. 
Description: 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable powder of low 
bulk density, having a faint odour of stearic acid and a characteristic taste. The powder is greasy 
to the touch and readily adheres to the skin. 
Solubility: 
Practically insoluble in ethanol (95%), ether and water; slightly soluble in warm benzene and 
warm ethanol (95%). 
Applications in Pharmaceutical Formulation or Technology: 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. It is 
primarily used as a lubricant in capsule and tablet manufacture at concentrations between 0.25% 
and 5.0% w/w. It is also used in barrier creams. 
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 Chemicals and Equipments used 
 Table 2: List of materials used 
 
 
 
S.No Materials Manufacturer Supplier 
1 Sorfenib Natco Pharma Ltd., Hyderabad Natco Pharma Ltd., 
Hyderabad 
2 Microcrystalline 
cellulose 
FMC Bio Polymer, New York 
 
Signet Chemical 
Corporation, Mumbai 
3 Croscarmellose FMC Bio Polymer, Ireland 
 
Signet Chemical 
Corporation, Mumbai 
4 Hypromellose 
 
Evonikdegussa Antwerpen 
 
Kancham Agencies, 
Tamil nadu 
5 Crospovidone ISP Technologies USA 
 
Anshul Agencies, 
Mumbai 
 
6 Magnesium 
stearate 
Luzenac Valchisone, Italy 
 
Signet Chemical 
Corporation, Mumbai 
7 Advantia Prime 
Pink 
Ferro Industriasquimicas, 
Portugal 
Signet Chemical 
Corporation, Mumbai 
8 Sodium starch 
glycolate 
DMV Fonterra Excipients Kamarlal & Co, 
Hyderabad 
9  Sodium lauryl       
sulphate 
 Ferro Corporations, USA 
 
Signet Chemical 
Corporation, Mumbai 
10 Purified water  Natco Pharma Limited 
 
Natco Pharma Limited 
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Table 3: List of equipments used: 
S.no  Equipment Company 
1     Electronic balance  
 
Metler Toledo, Mumbai 
 
2 Bulk density apparatus 
 
Electrolab, Mumbai 
 
3 Rapid mixer granulator 
 
Anchor, Mumbai 
 
4 Double cone blender 
 
Erweka 
 
5 Rotary Tablet punching machine 
 
Rimek, Mumbai 
 
6 Friability test apparatus 
 
Electrolab, Mumbai 
 
7 Tablet hardness tester Schleuniger hardness tester 
 
8 Disintegration test apparatus 
 
Electrolab , Mumbai 
 
9 Tablet dissolution apparatus 
 
Electrolab , Mumbai 
 
10 HPLC WATERS 
11 Pharma R&D coater Electrolab , Mumbai 
 
12 Stability chamber Thermolab 
 
Preformulation studies: [75] 
Preformulation studies are performed to investigate the physical and chemical 
properties of a drug substance alone and also when combined with other substances 
such as excipients. It is the first step in the rational development of dosage forms.  
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Objective: The overall objective of performing pre-formulation testing is to generate 
information that will be helpful in developing a stable and bioavailable dosage form 
when combined with excipients.  
 Scope: The use of pre-formulation parameters maximizes the chances in formulating 
an acceptable, safe, efficacious and stable product and at same time provides the basis 
for optimization of the drug -product quality.  
Organoleptic properties: The color, odour and taste of the drug were recorded using 
descriptive terminology.  
Angle of Repose: The flow property was determined by measuring the angle of 
repose. It is the maximum angle that can be obtained between the free standing 
surface of a powder heap and the horizontal.  
             Angle of repose= tan-¹ (h/r)  
             Where h = height and r = radius  
Procedure:  
20 gms of the sample was taken and passed through the funnel slowly, to form a heap. 
The height of the powder heap formed was measured and the circumference formed 
was drawn with a pencil on the graph paper. The radius was measured and the angle 
of repose was determined. This was repeated three times for a sample.  
Bulk density:  
Bulk density is ratio of given mass of powder and its bulk volume. Bulk density was 
determined by measuring the volume of known mass of powder sample that has been 
passed through the screen in to graduated cylinder.  
 Bulk density = M / V0  
 Where M= mass of the powder; V0=bulk volume of the powder.  
Limits: 
It has been stated that the bulk density values having less than 1.2 g/cm3 indicates 
good packing and values greater than 1.5 g/cm3 indicates poor packing. 
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Tapped density: [75] 
Tapped density was determined by USP method II. The powder sample under test 
was screened through sieve no.18 and 10 g of pure drug was filled in 100 mL 
graduated cylinder of tap density tester. The mechanical tapping of the cylinder was 
carried out using tapped density tester at a normal rate of 250 drops per minute for 
500 times initially and the initial tapped volume (Va) was noted. Tapping was 
proceeded further for additional 750 times and volume was noted. The difference 
between two tapping volumes was calculated.  
Tapping was continued for additional 1250 tap if the difference is more than 2%. This 
was continued in increments of 1250 taps until differences between volumes of 
subsequent tapping was less than 2%. This volume was noted as the final tapped 
volume (Vo). The tapped density (Dt) was calculated in g/mL by the formula: 
                 Tap density = M / Vo  
 Where M = mass of the powder, Vo = final tapping volume of the powder.  
Compressibility index and Hausner ratio: [76] 
In the recent years, the compressibility index and the closely related Hausner ratio 
have become the simple, fast, and popular methods of predicting powder flow 
characteristics.  
The compressibility index has been proposed as an indirect measure of bulk density, 
size and shape, surface area, moisture content, and cohesiveness of materials, because 
all of these can influence the observed compressibility index. The compressibility 
index and the Hausner ratio are determined by measuring both the bulk volume and 
tapped volume of a powder. 
Basic methods for the determination of compressibility index and Hausner ratio:  
While there are some variations in the method of determining the compressibility 
index and Hausner ratio, the basic procedure is to measure the unsettled apparent 
volume (VO), and the final tapped volume, (Vf), of the powder after tapping the 
material until no further volume changes occur.  
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The compressibility index and the Hausner ratio is calculated as follows:  
 Compressibility index = 100 × V0-Vf/V0  
Hausner ratio = V0/Vf  
 Where, V0 = apparent volume, Vf = final tapped volume.  
Alternatively, the compressibility index and Hausner ratio may be calculated using 
measured values of bulk density and tapped density as follows:  
Compressibility index = 100 × tapped density / bulk density  
Hausner ratio = tapped density / bulk density  
 In a variation of these methods, the rate of consolidation is sometimes measured 
rather than, or in addition to, the change in volume that occurs on tapping. For the 
compressibility index and the Hausner ratio, the generally accepted scale of flow 
ability is described in the following table.  
 Flow properties and corresponding Angle of repose, Compressibility index and 
Hausner ratio. 
Table 4: Flow properties determination 
S. No Flow properties Angle of 
repose(θ) 
Compressibility 
Index (%) 
Hausner ratio 
1 Excellent 25-30 <10 1.00-1.11 
2 Good 31-35 11-15 1.12-1.18 
3 Fair 36-40 16-20 1.19-1.25 
4 Passable 41-45 21-25 1.26-1.34 
5 Poor 46-55 26-31 1.35-1.45 
6 Very poor 56-65 32-37 1.46-1.59 
7 Very very poor > 66 >38 >1.6 
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Drug-Excipient compatibility studies:  
Drug is in intimate contact with one or more excipients in all the dosage forms. Later 
it could affect the stability of drug. Knowledge of drug-excipients interaction is useful 
in selecting an appropriate excipient. 
 Procedure: 
API and excipient are taken in the ratios mentioned elsewhere and mixed together in a 
polybag for 5 min. Each mixture is allotted with a sample code for identification. 4 
sets of sample were allocated where each sample mixture is divided into 1g and 
transferred to its corresponding glass vial (USP Type I) at different conditions.  
All vials are properly sealed and loaded at respective conditions. The samples 
checked for their description, related substance and water content by KF. The 
prepared drug and excipient mixtures were evaluated at various intervals for related 
substances by HPLC as per the following conditions and time intervals as per the 
procedure mentioned below. 
 
Table 5:  Sampling Schedule: 
S.No Condition Duration No. of Sets 
1 Initial 0 days 1 
2 550C ± 20C 14 days 1 
3 40 ± 20C & 75 ± 5% RH 14 days 1 
4 40 ± 20C & 75 ± 5% RH 28 days 1 
 
Then they are subjected for analysis of description, assay, loss on drying and purity.  
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Solubility studies:  
Solubility was determined by adding the solute in small incremental amount to fixed 
volume of the solvents. After each addition, the system was vigorously shaken and 
examined visually for any undissolved solute particles. Solubility of acid or base drug 
is pH dependent. It is determined over the pH range 1-8.  
Water Content: 
35 mL of a mixture of methanol was transferred to the titration vessel and titrated 
with Karl Fischer reagent to the electrometric end point, to consume any moisture that 
may be present (disregard the volume consumed, since it does not enter into the 
calculation). Accurately 350 mg of the drug was weighed and transferred in to the 
titration vessel, mixed and titrated with the KF reagent to the electrometric endpoint. 
The water content of the specimen in mg taken by the formulae: 
Calculation: 
Water (%) = S X F X 100 
           W 
Where, 
 S = Volume in ml of reagent consumed in the second titration 
 F = Water equivalent factor of KF reagent 
 W = Weight of sample taken in mg 
Loss on drying (LOD): 
The Loss on drying test is designed to measure the amount of water and volatile 
matters in a sample when the sample is dried under specified conditions. The loss on 
drying of the blend (2 g) was determined by using electronic LOD apparatus at 
105°C. 
EVALUATION OF TABLETS: [77] 
The quantitative evaluation and assessment of a tablets chemical, physical and 
bioavailability properties are important in the design of tablets to monitor product 
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quality. There are various standards that have been set in the various pharmacopoeias 
regarding the quality of pharmaceutical tablets. These include the diameter, size, 
shape, thickness, weight, hardness, disintegration and dissolution characters 
1. Physical Appearance:  
The general appearance of a tablet, its identity and general elegance is essential for 
consumer acceptance, for control of lot-to-lot uniformity and tablet-to-tablet 
uniformity. The control of general appearance involves the measurement of size, 
shape, colour, presence or absence of odour, taste etc.  
2. Size & Shape:  
It was dimensionally described & controlled. The thickness of a tablet is only 
variables. Tablet thickness was measured by micro-meter. Tablet thickness should be 
controlled within a limit of ± 5% variation of standard value.  
3. Weight variation test:  
This is an in process quality control test to ensure that the manufacturers control the 
variation in the weight of the compressed tablets. Different pharmacopoeias specify 
different limits for these weight variation tests. These tests are primarily based on the 
comparison of the weight of the individual tablets of a sample of tablets with an upper 
and lower percentage limit of the observed sample average. The USP has provided 
limits for the average weight of uncoated compressed tablets. These are applicable 
when the tablet contains 50mg or more of the drug substance or when the later 
comprises 50% or more, by weight of the dosage form.  
Method: 
Twenty tablets were weighed individually and the average weight was calculated. The 
individual tablet weights are then compared to the average weight. As per USP not 
more than two tablets should differ in their average weight by more than percentages 
stated and no tablet must differ by more than double the relevant percentage. 
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Table 6: Limits for tablet weight variation test:  
Average weight of tablet (mg) % Difference allowed 
130 or less 10 % 
From 130 to 324 7.5 % 
> 324 5 % 
  
4. Content Uniformity: 
The content uniformity test is used to ensure that every tablet contains the amount of 
drug substance intended with little variation among tablets within a batch.  
Method:  
Randomly 30 tablets were selected and 10 of these were assayed individually. 
According to the quality standards the tablet pass the test if 9 of the 10 tablets must 
contain not less than 85% and not more than 115% of the labeled drug content and the 
10th tablet may not contain less than 75% and more than 125% of the labeled content. 
If these conditions are not met, remaining 20 tablets were assayed individually and  
none may fall outside of the 85 to 115% range.  
ASSAY OF SORAFENIB [78] 
The sorafenib content in each tablet was assayed by HPLC method using X-Terra RP- 
18 column- (100 x 4.6 mm, 5 µm)  by injecting 20 µL of sample with a flow rate of 
2.0 mL/ minute and a run time of 15 minutes at an ambient temperature using a UV 
detector at 293 nm. 
Preparations: 
Buffer preparation:  
2.72 g of potassium di hydrogen orthophosphate was weighed accurately and 
transferred in to 1000 mL standard flask and the volume made with distilled water. 
pH was made to 3.0 with orthophosphoric acid.  
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Mobile phase preparation: 
Phosphate Buffer, Acetonitrile and Tetrahydrofuran in the ratio of 530:395:75 v/v 
was prepared and filtered through 0.22 µm membrane filter and degassed. 
Diluent preparation: 
Methanol and Acetonitrile in the ratio of 50:50 v/v was prepared and filtered in a 
membrane filter and degassed. 
26.2 mg of sorafenib tosylate was weighed and transferred to 100 mL of volumetric 
flask added with 60 mL of dissolution medium and sonicated to dissolve. The 
solution was cooled to room and 5.0 mL of the standard stock preparation transferred 
to a 100 mL volumetric flask and volume made with dissolution medium [79].  
Sample preparation:  
20 tablets of sorafenib were taken and powdered. From this powder equivalent to   
200 mg of Sorafenib was transferred into a 250 mL volumetric flask and added with 
160 mL of dissolution medium. The resulting mixture was shaken for 15 minutes on 
orbital shaker and sonicated for 30 minutes with occasional shaking. The mixture was 
cooled to room temperature and the volume was made with dissolution medium and 
filtered through 0.22 µm membrane filter. From the above solution 3.0 mL was taken 
and made to 250 mL in a volumetric flask using dilution medium [80]. 
System suitability:  
Chromatograph the standard preparation (Six replicate injections), measure the peak 
area responses for the analyte peak and evaluate the system suitability parameters as 
directed.  
Acceptance criteria:  
% RSD for replicate injections of peak area response of the sorafenib peak from the 
standard preparation should be not more than 2.0  
The Tailing factor for sorafenib peak should be not more than 2.0  
The number of theoretical plates for sorafenib peak should be not less than 2000.  
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Procedure:  
20 µL of the diluent as blank, standard preparation and sample preparation were 
injected separately into the chromatograph and peak area responses for the analyte 
were recorded and measured. Content of sorafenib(%) in the portion of sorafenib 
tablets was calculated by the formula. 
5. Thickness and diameter: The thickness and diameter of 10 tablets were recorded 
during the process of compression using vernier calipers. 
6. Hardness:  
Hardness, more appropriately called crushing strength is used to determine the need 
for pressure adjustment on tablet machine. If the tablet is too hard, it may not 
disintegrate in the required period of time to meet the dissolution specifications; if it 
is too soft, it may not be able to withstand the handling during subsequent processing 
such as coating or packaging and shipping operations [81]. The force required to break 
the tablet is measured in kilograms. The small and portable hardness tester measures 
the force required to break the tablet when the force generated by a coil spring is 
applied diametrically to the tablet.  
7. Friability:  
Friction and shock are the forces that most often cause tablets to chip, cap or break. 
The friability test is closely related to tablet hardness and designed to evaluate the 
ability of the tablet to withstand abrasion in packaging, handling and shipping. It is 
usually measured by the use of the Roche friabilator.  
Method:  
20 tablets were weighed and placed in the apparatus where they are exposed to rolling 
and repeated shocks as they fall 6 inches in each turn within the apparatus. After four 
minutes of this treatment or 100 revolutions, the tablets are weighed and the weight 
compared with the initial weight. The loss due to abrasion is a measure of the tablet 
friability. The value is expressed as a percentage. A maximum weight loss of not 
more than 1% of the weight of the tablets being tested during the friability test is 
considered generally acceptable and any broken or smashed tablets are not picked.  
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The percentage friability was determined by the formula:  
 % Friability = (W1-W2) / W1 X 100  
 W1 = Weight of tablets before test  
 W2 = Weight of tablets after test  
8. Disintegration test:  
For a drug to be absorbed from a solid dosage form after oral administration, it must 
first be in solution, and the first important step toward this condition is usually the 
break-up of the tablet; a process known as disintegration. The disintegration test is a 
measure of the time required under a given set of conditions for a group of tablets to 
disintegrate into particles which will pass through a 10 mesh screen. Generally, the 
test is useful as a quality assurance tool for conventional dosage forms [82].  
Method:  
The U.S.P. device to test disintegration uses 6 glass tubes that are open at the top and 
10 mesh screen at the bottom end. To test for disintegration time, one tablet is placed 
in each tube and the basket rack is positioned in a 1-L beaker of water, simulated 
gastric fluid or simulated intestinal fluid at 37 ± 2° C such that the tablet remain 2.5 
cm below the surface of liquid on their upward movement and not closer than 2.5 cm 
from the bottom of the beaker in their downward movement. The basket containing 
the tablets was moved up and down through a distance of 5-6 cm at a frequency of 28 
to 32 cycles per minute. Floating of the tablets can be prevented by placing perforated 
plastic discs on each tablet. According to the test the tablet must disintegrate and all 
particles must pass through the 10 mesh screen in the time specified. If any residue 
remains, it must have a soft mass. If one or two tablets fail to disintegrate, the test is 
repeated using 12 tablets.  
Disintegration time:    Uncoated tablet: not more than15 minutes  
       Coated tablet: not more than 30 minutes 
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9. Dissolution:  
Dissolution is the process by which a solid solute enters a solution [83]. In the 
pharmaceutical industry, it may be defined as the amount of drug substance that goes 
into solution per unit time under standardized conditions of liquid/solid interface, 
temperature and solvent composition. Dissolution is considered one of the most 
important quality control tests performed on pharmaceutical dosage forms and is now 
developing into a tool for predicting bioavailability [84].  
 
Evaluation of dissolution profile of sorafenib tablet :  
The dissolution test was carried out for the prepared tablets was carried out in USP 
type-2 (Paddle) apparatus using 900 mL of 0.1M Hydrochloric acid with 1% SDS as 
medium at a temperature of 37 ºC ± 0.5 ◦C with a paddle speed of 75 rpm. Samples 
were withdrawn at 5, 10, 15, 20 and 30 minutes time interval for the content 
evaluation.  
Preparation of Dissolution medium (0.1M Hydrochloric acid with 1% SDS): 
8.5 mL of hydrochloric acid was pipetted out to a standard flask and volume made to  
1000 mL with distilled water 
Chromatographic conditions:  
Column- X-Terra RP- 18 (100 x 4.6 mm), 5 µm  
Flow rate – 2.0 mL/ minute  
Wavelength- UV-293 nm  
Column temperature- Ambient  
Injection volume- 10 µL  
Run time- 15 minutes  
Preparations: 
Buffer preparation: Accurately 2.72 g of Potassium dihydrogen orthophosphate was 
weighed and transferred into 1000 mL of purified water and mixed well. The solution 
pH was adjusted to 3.0 with dilute orthophosphoric acid. 
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Mobile phase preparation: Mixture of Buffer, Acetonitrile and Tetrahydrofuran in 
the ratio of 530:395:75 V/V were prepared and was filtered through 0.22 µm 
membrane filter and degassed. 
Standard preparation:  
About 26.2 mg of sorafenib tosylate was accurately weighed and transferred into    
100 mL volumetric flask and added with 60 mL of dissolution medium and sonicated 
to dissolve. The solution was cooled to room temperature and diluted to volume with 
dissolution medium. 5.0 mL of the standard stock preparation was transferred into a 
100 mL volumetric flask and dilute to volume with dissolution medium.  
Sample preparation:  
One tablet of sorafenib was kept in each of six dissolution flasks containing 900 mL 
of dissolution medium, previously maintained at 37ºC, taking care to exclude air 
bubbles from the surface of each dosage unit and immediately operate the apparatus 
for specified time intervals. After completion of each specified time interval, 2 mL 
portion of solution from zone midway between the surface of the dissolution medium 
and top of the rotating blade, not less than 1cm from vessel wall and filtered through 
0.22 µm membrane filter.  
2.0 mL of the above solution was transferred into a 20 mL volumetric flask and 
volume diluted to mark with dissolution medium.  
System suitability:  
The chromatogram for the standard preparation (Six replicate injections), the peak 
area responses measured for the analyte peak and evaluated the system suitability 
parameters as directed.  
Acceptance criteria:  
% RSD for replicate injections of peak area response of sorafenib peak from the 
standard preparation should not be more than 2.0.  
The Tailing factor for sorafenib peak should be not more than 2.0. 
The number of theoretical plates for sorafenib peak should be not less than 2000.  
 
Chapter 6  Materials and Methods 
Department of Pharmaceutics Page 59 
 
Procedure:  
10 µL of the dissolution medium as blank, standard preparation and sample 
preparation were injected separately into chromatograph and chromatograms were 
recorded for peak area responses. The % of drug content (sorafenib) in the portion of 
sorafenib tablets was then calculated  
Related Impurities: 
Chromatographic conditions:  
The level of related impurities were assayed by HPLC using X-Terra RP- 18 column- 
(100 x 4.6 mm, 5 µm)  by injecting 10 µL of sample with a flow rate of 0.8 mL/ 
minute and a run time of 45 minutes at 30○C using a UV detector at 265 nm and 293 
nm. 
Preparations: 
Buffer preparation: 
2.72 g 0f Potassium Dihydrogen Orthophosphate was weighed and transferred into 
1000 mL of purified water and mixed well. The solution pH was adjusted to 3.0 with 
dilute orthophosphoric acid. 
Mobile phase-A preparation: 
Buffer preparation was used as mobile phase-A. it was filtered through 0.22 µm 
membrane filter and degassed. 
Mobile phase-B preparation: 
Mixture of Acetonitrile and Tetrahydrofuran in the ratio of 90:10 v/v was prepared 
and the solution was filtered through 0.22 µm membrane filter and degassed. 
Diluent preparation: 
Prepare a filtered and degassed mixture of Methanol and Acetonitrile in the ratio of 
50:50 v/v respectively. 
 
Chapter 6  Materials and Methods 
Department of Pharmaceutics Page 60 
 
Placebo preparation: 
Placebo powder equivalent to 100 mg of sorafenib was weighed accurately and 
transferred into a 200 mL volumetric flask and added with 160 mL of dilution 
medium and sonicated for 20 minutes with occasional shaking. The solution was 
cooled to room temperature and the volume was made and filtered through 0.22 µm 
membrane filter and degassed. 
Peak Identification solution preparation: 
About each 5.0 mg of Impurity-A, impurity-B, Impurity-C was accurately weighed 
and transferred into a 50 mL volumetric flask, added with 30 mL of dilution medium 
and sonicated to dissolve. The solution was cooled and the volume was made. 
137.0 mg of sorafenib tosylate working standard (equivalent to 100 mg of sorafenib) 
was weighed and transferred into a 200 mL volumetric flask. 160 mL of dilution 
medium was added and sonicated for 20 min with occasional shaking. The resulting 
solution was cooled to room temperature, added with 2.0 mL of Peak Identification 
solution and volume dilute to mark with diluents medium. 
Standard preparation: 
14 mg of sorafenib tosylate working standard was accurately weighed and transferred 
into a 200 mL volumetric flask, added with 160 mL of dilution medium and sonicated 
to dissolve. Solution was cooled to room temperature and volume was made to the 
mark with dilution medium. 
1 mL of the above solution was transferred into a 100 mL volumetric flask and 
volume made with dilution medium. 
Sample preparation: 
20 tablets of sorafenib was powdered and powder equivalent to 100 mg of sorafenib 
was transferred into a 200 mL volumetric flask, added 160 mL of dilution medium, 
sonicated for 20 minutes with occasional shaking. The solution was cooled to room 
temperature volume was made and filtered through 0.22 µm PVDF filter. 
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System suitability: 
The standard preparation (six replicate injections) and Peak Idenification solution 
(one injection) was chromatogramed and the peak area responses for the analyte 
peaks and evaluate the system suitability parameters as directed. 
Acceptance criteria: 
• % RSD for six replicate injections of peak area response for sorafenib peak   
(at 235 nm) from the standard preparation should be not more than10.0. 
• %RSD for six replicate injections of peak area response for sorafenib peak   
(at 265 nm) from the standard preparation should be not more than 5.0. 
• Tailing factor for sorafenib peak from standard preparation should not be 
more than 2.0. 
• The number of theoretical plate count for sorafenib peak from standard 
preparation should not be less than 2000. 
• Resolution between Impurity-C and sorafenib from peak identification 
solution should not be less than 1.5. 
Procedure: 
10 µl of diluent as blank, placebo preparation, peak identification solution 
preparation, blank, standard preparation and sample preparation were injected 
separately into the chromatograph and the chromatograms were recorded. The % of 
each impurity in the portion of sorafenib tablets was then calculated. 
Water content (By KF Method): 
Instrument: Karl Fischer titrator 
35 mL of a mixture of methanol was transferred to the titration vessel and titrated 
with Karl Fischer reagent to the electrometric end point, to consume any moisture that 
may be present (disregard the volume consumed, since it does not enter into the 
calculation). 350 mg of the powder was accurately weighed and transferred into the 
titration vessel, mixed and titrated with Karl Fischer reagent to the electrometric end 
point. Finally the water content of the specimen in mg was calculated. 
 
Chapter 6  Materials and Methods 
Department of Pharmaceutics Page 62 
 
Stability studies: 
The purpose of stability testing is to provide evidence of the quality of the drug 
substance or drug product, and how it varies with time under the influence of a 
variety of environmental conditions (heat, humidity, light, air etc). The final 
formulation was packed in suitable packing like blister and strip packs and then they 
will be kept at different temperature, humidity conditions and the samples will be 
analyzed for their physical and chemical properties.  
 
Table 7: ICH guide lines for Stability Study 
Study Storage condition Time period 
Long term 25°C±2°C/60% RH±5% RH 
or 
30°C±2°C/65% RH±5% RH 
12 month 
Intermediate 30°C±2°C/65% RH±5% RH 6 month 
Accelerated 40°C±2°C/75% RH±5% RH 6 month 
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Experimental Investigation 
Innovator product details: 
Product name : Nexavar 
Label claim : Each tablet contains 200 mg of sorafenib 
Manufactured by : Bayers health care 
Description : Red in colour, debossed with Bayer cross on one side 
and 200 on other side  
Inactive ingredients : Inactive ingredients of the tablets are Microcrystalline 
cellulose, Croscarmellose, 
Hydroxypropylmethylcellulose, Magnesium stearate.  
 Thickness : 4.44 mm  
Width : 7.64 mm  
Diameter : 10.05 mm  
Storage : Store at 25°C (77°F); 
Dissolution Apparatus : Paddle type (USP apparatus II) 
Dissolution Medium  : 0.1M Hydrochloric acid with 1% SDS 
Dissolution medium Volume : 900 mL  
Time points  : 5, 10, 15, 20, 30 minutes  
Speed  : 75 rpm 
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FORMULATION DEVELOPMENT  
Procedures:  
Table 8. List of excipients used in the formulation: 
Purpose Ingredients 
Diluent Microcrystalline cellulose 
Binder Hypromellose 
Disintegrant Croscarmellose 
Solubility enhancer Sodium lauryl sulphate 
Lubricant Magnesium stearate 
Colourant Advantia Prime Pink 
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Table 9: Composition of Sorafenib Tosylate tablets: 
 Ingredients  
 
 F1 
(mg) 
 F2 
(mg) 
 F3* 
(mg) 
 F4 
(mg) 
 F5 
(mg) 
 F6 
(mg) 
 F7  
(mg) 
 F8 
(mg) 
 F9 
(mg) 
 F10 
(mg) 
 F11 
(mg) 
Sorafenib 
tosylate 
274.0 274.0 274.0 274.0 274.0 274.0 274.0 274.0 274.0 274.0 274.0 
Avicel  60.55 60.55 57.50 57.50 57.50 65.30 49.70 41.90 61.40 53.60 49.70 
Croscarmellose  37.00 37.00 39.00 - - 31.20 46.80 54.60 39.00 39.00 39.00 
Crospovidone - - - 39.00 - - - - - - - 
Sodium 
starchglycolate 
- - - - 39.00 - - - - - - 
Hypromellose  7.80 7.80 7.80 7.80 7.80 7.80 7.80 7.80 7.80 7.80 7.80 
Sodium lauryl 
sulphate 
7.80 7.80 7.80 7.80 7.80 7.80 7.80 7.80 3.90 11.70 15.60 
Magnesium 
stearate 
2.85 2.85 3.90 3.90 3.90 3.90 3.90 3.90 3.90 3.90 3.90 
Purified water - - q.s q.s q.s q.s q.s q.s q.s q.s q.s 
Advantia 
Prime Pink 
10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 
Total   (mg) 400 
mg 
400 
mg 
400 
mg 
400 
mg 
400 
mg 
400 
mg 
400 
mg 
400 
mg 
400 
mg 
400 
mg 
400 
mg 
*-Optimized formula 
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Procedure for Formulation 1: (Direct compression): [85] 
API, microcrystalline cellulose PH102, croscarmellose, sodium lauryl sulphate were 
weighed and sifted individually through 40 # mesh. All the ingredients were 
transferred to poly bag and mixed for 3 minutes and the blend was passed through 40 
# mesh and mixed thoroughly.  Magnesium stearate used as lubricant was weighed 
separately, sieved through 40 # mesh and blended with the ingredients for 2 minutes. 
The mixture was compressed using oblong punches.  
Procedure for Formulation 2: (Slugging) [85] 
API, microcrystalline cellulose PH102, croscarmellose, hypromellose, sodium lauryl 
sulphate were weighed accurately and mixed in a polybag for 10 minutes and sifted 
through 40 # mesh.  Weighed quantity of magnesium stearate sifted through 40 # 
mesh was then added to above blend and mixed for 2 min in a poly bag.  Lubricated 
blend is slugged with 18 mm round flat punches. Slugs obtained were milled in 
multimill using 8mm mesh and further milled with 2mm mesh. The granules obtained 
were passed through 18 # mesh. 
Procedure for Formulation 3 to 11: (Wet Granulation) [86] 
 Ingredients such as API, microcrystalline cellulose PH101were weighed and sifted 
individually through 40 # mesh and transferred to poly bag and mixed for 10 minutes 
and the blend was passed through 40 # mesh. Binder solution was prepared by 
dissolving hydroxypropyl methyl cellulose in sufficient quantity of purified water and 
added to the blend. The wet mass was passed through 12 # mesh and the granules 
obtained were dried at 60°C for 30 minutes. Dried granules were passed through 18 # 
mesh. Above prepared granules were lubricated with magnesium stearate and passed 
through 40 # mesh and was compressed using punches. Tablets obtained were coated 
using Advantia Prime Pink (coating material) for weight gain of each tablet up to 1% 
(where formulation1 and 2 is uncoated).  
* In formulation 3, 4, 5; 39 mg of each of croscarmellose, sodium starch glycolate, 
crospovidone was taken as disintegrant respectively. 
* In formulation 6, 7, 8 disintegrant concentrations were altered such as 8%, 12%, 
14% concentration of croscarmellose was taken.  
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* In the formulation 9, 10, 11; sodium lauryl sulphate concentration was taken as 1%, 
3% and 4% respectively. 
* In formulation 12; the F3 formulation was increased to a batch size of 2000 tablets. 
Procedure for Film Coating [87] 
Film coating was done for the tablets to give a good appeal and to increase the elegance. 
The tablets were charged into the pan of coating machine (Ideal cures) and coated using 
Advantia Prime Pink. Adavntia Prime Pink composes of hydroxyl propyl methyl 
cellulose,  hypromellose, polyethyleneglycol, titanium di oxide and ferric oxide red.  The 
coating solution was prepared by dispersing Advantia Prime Pink (10%) in water and was 
sprayed over the tablets using 1.5 mm air nozzle with an atomizing air pressure of 3-4 
atm. The pan speed was maintained at 30 rpm with an inlet and Outlet temperature 
maintained at 600C and 550C respectively. The coating was performed until required 
weight gain of 1% was obtained. 
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 Evaluation of Preformulation parameters: 
Micromeritic properties of excipients:  
The results of  compressibility index, angle of repose and Hausner’s ratio were mentioned in the 
table below.  
Table 10:  Micromeritic properties of excipients 
Ingredient Bulk 
density(g/cm3) 
Tapped 
density(g/cm3) 
Angle of 
repose(ф) 
Compresibility 
index (%) 
Hausners 
ratio 
Avicel pH101  1.62±0.13 
 
1.43±0.18 
 
30.4±0.08 
 
12.9 
 
1.16 
 
Hypromellose  1.43±0.20 
 
1.32±0.12 
 
37.9±0.11 
 
17.2 
 
1.22 
 
croscarmellose 1.02±0.27 
 
0.87±0.23 
 
38.4±0.09 
 
19.1 
 
1.26 
 
Sodium starch 
glycolate 
1.09±0.5 0.9±0.28 43.8±0.6 19.9 1.31 
Crospovidone 1.06±0.2 0.96±0.11 36.1±0.3 18.6 1.18 
Magnesium 
stearate  
1.98±0.11 
 
1.09±0.09 
 
36.5±0.08 
 
    18.5 
 
1.24 
 
Sodiumlauryl 
sulphate  
1.08±0.2 1.99±0.21 
 
29.8±0.23 
 
16 
 
0.9 
 
 
Inference: 
All the excipients used in the formulation were shown the above results for micrometric evaluation 
parameters. Compressibility index of all the ingredients was found in between 12 to 19, indicates 
poor compressibility index.  Angle of repose of all formulations are found to be between 30 to 38,  
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indicating all the excipients are possessing good flow properties and Hausner ratio of all excipients 
was found to be 1.0 to 1.2, which satisfies the limits of compressibility.    
API (Active Pharmaceutical Ingredient) Characterization: 
Table 11: Micromeritic properties of Active Pharmaceutical Ingredient: 
 
 
 
 
 
 
 
Inference: Based on the above pre-formulation results it was observed that the flow was poor and 
wet granulation method was suitable. 
                                         
 
 
 
 
 
 
 
S.No Parameter Results 
1 Angle of repose 36.50± 0.12 
2 Bulk Density 0.72±0.3 gm/ml 
3 Tapped Density 0.54±0.2gm/ml 
4 Compressibility Index 39.6±0.5% 
5 Hausner’s ratio 1.32±0.29 
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 EVALUATION OF GRANULES 
Table 12: Evaluation of different parameter for the trial formulation  
S.No Formulations 
Bulk 
Density 
(g/ml) 
Tapped 
Density  
(g/ml) 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
1 F-1 0.519 0.732 29.09 1.443 
2 F-2 0.436 0.500 12.8 1.14 
3 F-3 0.445 0.505 11.8 1.13 
4 F-4 0.408 0.480 13.74 1.15 
5 F-5 0.416 0.485 14.2 1.16 
6 F-6 0.393 0.460 14.5 1.17 
7 F-7 0.428 0.490 12.6 1.14 
8 F-8 0.415 0.476 12.8 1.14 
9 F-9 0.428 0.496 13.7 1.15 
10 F-10 0.400 0.470 14.8 1.17 
11  F-11 0.417 0.482 13.4 1.15 
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Solubility Profile: 
Table 13: Solubility data of Sorafenib tosylate: 
 
 
Inference:  
The above values of concentrations indicate the solubility of Sorafenib tosylate in different  solvents. 
It was observed that the solubility of sorafenib in water is very low and in acidic media it shows 
better solubility profile  
 Drug-excipient compatibility studies: 
Compatibility studies were conducted for drug and excipients in separate as well as in combination 
with different proportions at different temperature conditions for a period of two weeks and for four 
weeks. Here the external appearance of tablets was considered as the criteria i.e. color. After four 
weeks of studies all the combinations which are undergone for testing evaluated for appearance. And 
all the formulations showed no change in color during studies. 
     
 
 
S. No. Buffers Solubility (mg/ml) 
1 Water 171 
2 0.1N HCl 634 
3 PEG 260 
4 Phosphate Buffer pH 6.8 180 
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Results of Drug-excipient compatibility studies: 
Table 14: Descriptions of drug excipients 
S.No Ingredients Quantity 
(mg) 
Description 
Initial 55°C      
(2weeks) 
40±2°C /75±5 % RH    
(4weeks) 
1 API 1 Off white No change No change 
2 Avicel 1 Off white No change No change 
3 Croscarmellose 1 White No change No change 
4 Hypromellose 1 White No change No change 
5 SLS 1 white No change No change 
6 Magnesium stearate 1 White No change No change 
7 Advantia Prime Pink 1 Brick Red No change No change 
8 API+Avicel 5:1 Off White No Change No Change 
9 API+Hypromellose 5:1 Off white No change No change 
10 API+Croscarmellose 5:1 Off white No change No change 
11 API+ SLS 5:1 Off white No change No change 
12 API+ Crospovidone 5:1 Off white No change No change 
13 API+ Sodium starch 
glycolate 
5:1 Off White No Change No Change 
14 API+ Advantia Prime 
Pink 
5:1 Light 
Brown 
No Change No Change 
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Inference:  By the physical examination of the mixture of excipient, it was observed that there is no 
change in the colour of the mixtures even after 4 weeks. So it indicates that there are no interactions 
between drug and excipients. 
 COMPATIBILITY STUDY SPECIFICATIONS 
Table 15: Specifications of the relative substances 
RELATIVE 
SUBSTANCE 
SPECIFICATIONS (%) 
Impurity A NMT 0.2% 
Impurity B NMT 0.2% 
Impurity C NMT 0.2% 
Highest unknown 
impurity 
NMT 0.2% 
Total impurity NMT 1.5% 
 
Table 16: Relative substances in Sorafenib tosylate 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.016 0.016 0.023 
Impurity B ND ND ND 
Impurity C 0.050 0.056 0.056 
Highest unknown 
impurity 
0.013 0.012 0.012 
Total impurity 0.079 0.084 0.091 
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Table 17: Relative substances in Sorafenib +Micro Crystalline Cellulose 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.014 0.017 0.015 
Impurity B ND ND ND 
        Impurity C 0.043 0.043 0.041 
Highest unknown 
impurity 
0.009 0.011 0.009 
Total impurity 0.071 0.073 0.065 
 
 
 
Table 18: Relative substances in Sorafenib + Croscarmellose sodium 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.014 0.015 0.016 
Impurity B ND ND ND 
Impurity C 0.045 0.045 0.043 
Highest unknown 
impurity 
0.013 0.011 0.010 
Total impurity 0.072 0.074 0.069 
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Table 19: Relative substances in Sorafenib + Sodium Lauryl Sulfate 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.017 0.019 0.019 
Impurity B ND ND ND 
Impurity C 0.042 0.049 0.067 
Highest unknown 
impurity 
0.013 0.011 0.011 
Total impurity 0.072 0.083 0.097 
 
 
Table 20: Relative substances in Sorafenib + HPMC E5 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.014 0.021 0.020 
Impurity B ND ND ND 
Impurity C 0.045 0.049 0.051 
Highest unknown 
impurity 
0.011 0.012 0.012 
Total impurity 0.070 0.086 0.083 
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Table 21: Relative substances in Sorafenib + Magnesium Stearate 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.019 0.020 0.019 
Impurity B ND ND ND 
Impurity C 0.055 0.053 0.052 
Highest unknown 
impurity 
0.012 0.012 0.012 
Total impurity 0.084 0.091 0.083 
 
 
Table 22: Relative substances in Sorafenib + Advantia Prime Pink 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.018 0.015 0.019 
Impurity B ND ND ND 
Impurity C 0.052 0.052 0.050 
Highest unknown 
impurity 
0.012 0.013 0.012 
Total impurity 0.082 0.085 0.081 
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Table 23: Relative substances in Sorafenib + Sodium Starch Glycolate 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.24 0.26 0.25 
Impurity B ND ND ND 
Impurity C 0.40 0.43              0.40 
Highest unknown 
impurity 
0.012 0.011 0.009 
Total impurity 0.076 0.078 0.072 
Table 24: Relative substances in Sorafenib + Crospovidone 
RELATIVE 
SUBSTANCE 
INITIAL 14 DAYS 28 DAYS 
Impurity A 0.25 0.26 0.28 
Impurity B ND ND ND 
Impurity C 0.046 0.046 0.044 
Highest unknown 
impurity 
0.013 0.012 0.010 
Total impurity 0.074 0.075 0.070 
      
 Impurity A:   4-(2-(N-methyl carbonyl)-4-pyrydyloxy) aniline. 
Impurity B:   1, 3-Bis (4-chloro-3-di floro phenyl) phenyl urea 
Impurity C: 4 (4- ((((2-chloro-3-tri floro methyl) phenyl) amino) carbonyl) amino)-phenyl)-N- 
methyl-2-pyridine carboxamide tosylate. 
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Discussion: 
The increase in impurities at the initial stage is found in sodium starch glycolate and Crospovidone. 
So these are incompatible with active ingredient. Hence, it is recommended that the above excipients 
cannot be used in further formulation development trials. 
 
 Calibration of Standard Graph of Sorafenib Tosylate: 
Standard graph of Sorafenib : 
The construction of standard calibration curve of Sorafenib tosylate was done by using 0.1M 
Hydrochloric acid as the medium. From the stock solution, calibration standards were prepared by 
adding different concentration of the sorafenib solution and volume made with the mobile phase to 
yield the final respective concentration of 6.55, 10.48, 11.79, 13.1, 14.41, 15.92 and 19.65 µg/ml. 
The standard solutions were injected separately and the chromatogram was recorded using a UV 
detector at 293 nm. The standard graph of Sorafenib tosylate was constructed by taking the peak area 
on Y-axis and concentrations on X-axis. 
Table 25: Peak area responses of Sorafenib tosylate.                 
  S.no   % Level Concentration(µg/ml)    Peak Area 
    1 
        50                6.55       193481 
    2         80               10.48       309568 
    3         90               11.79       348265 
    4 
       100               13.10       386961 
    5        110               14.41       425657 
    6        120               15.72       464353 
    7 
       150               19.65       580442 
 
 
                  
 
 
Chapter 7  Results and discussion 
Department of Pharmaceutics Page 79 
 
 
    
Standard graph of Sorafenib: 
 
 
Fig. 5. Standard graph of Sorafenib. 
 
 Evaluation of the Prepared Tablets for Physical Parameters:  
All formulations were tested for Physical parameters like hardness, thickness, weight variation, 
friability and found to be within the Pharmacopoeial limits. The results of the tests were tabulated. 
The drug content of all the formulations was determined and was found to be within the permissible 
limit. This study indicated that all the prepared formulations were good. 
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Table 26: Results for evaluation parameters of all formulations  
S.No Formulations Thickness 
(mm) 
Hardness 
(kg/cm2) 
Disintegration 
(Min) 
Friability 
(%) 
Assay 
(%) 
1 F-1 5.5±0.4 8.9±1.4 9.29 0.08 97.3 
2 F-2 4.62±0.016 15.1±0.03 9.02 0.06 97.5 
3 F-3 5.45 ±0.024 13.4 ±0.51 5.53 0.15 99.9 
4 F-4 4.86 ±0.035 14.19±0.22 8.5 0.09 94.1 
5 F-5 4.9± 0.016 14.1 ± 0.27 18 0.1 98.2 
6 F-6 4.67 ±0.052 14.78±0.59 20 0.08 92.4 
7 F-7 5.42 ±0.022 13.6±0.47 5.7 0.16 99.7 
8 F-8 5.64 ±0.019 13.4 ± 0.35 5.42 0.14 98.5 
9 F-9 4.86 ±0.035 14.19±0.22 8.5 0.09 94.1 
10 F-10 5.82± 0.029 13.04±0.49 15 0.18 97.4 
11 F-11 5.07 ±0.053 14.46±0.32 8.29 0.09 98.3 
12 Innovator 5.44 ± 0.04 13.5 ± 0.51 5.55 0.15 98.8 
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ASSAY( by HPLC): 
Fig. 6. Chromatogram of Sorafenib 
 
 
Fig. 7 . Chromatogram of Sorafenib tosylate 
 
 
tosylate standard preparation
in sample preparation
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Inference: Sorafenib assay was carried by HPLC method by using UV-detectors. The above 
chromatograms are indicating Sample and Standard chromatograms respectively. Content uniformity 
was calculated from the above chromatograms peak area responses. 
 
In vitro Dissolution studies:  
The dissolution conditions used for studying the drug release from tablet of Sorafenib tosylate are: 
Apparatus    : USP apparatus II (Paddle) 
Agitation speed (rpm)             : 75 rpm 
Medium              : 0.1N HCl with 1%SDS 
Volume                                     : 900 ml 
Temperature              : 37.0 ± 0.5○ C 
Time               : 5, 10, 15, 20 and 30 min. 
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Results of Dissolution profile:  
Table 27: Cumulative % drug release of different formulation 
S.No Time F- 3   F-4 F-5 F-6 F-7 F-8 F-9 F-10 F-11 Innovator 
1 0 0 0 0 0 0 0 0 0 0 0 
2 5 75.2 70 71.6 60.4 72.2 73.15 50.5 72.8 73.4 73.80 
3 10  87.5 75.2 77.8 62.2 78.4 78.3 55.2 80.5 78.6 88.70 
4 15 95.8 82.3 81.2 70.1 86.9 83.1 70.3 87.2 85.3 92.30 
5 20 97.5 88.9 87.4 75.2 90.5 89.9 72.5 90.4 89.2 93.80 
6 30 97.7 92 92.7 78.6 96.10 94.10 75.1 93.40   92.8 94.90 
 
F - 3 as the best formulation as it showed total drug release with in 30 min than all other 
formulations when compared to the reference product.  
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         Comparision of dissolution profile: 
 
 
 
 
 
 
 
 
 
Fig. 8. Comparative in vitro dissolution studies with innovator product 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Comparative dissolution profile for optimized and reference product 
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Inference: Among the all formulations, formulation 3 shows best dissolution profile, when 
compared to other formulations. This is because of use of 10% concentration of super disintegrant, 
croscarmellose act by swelling mechanism. Hence these mechanism aids in the faster release of the 
drug from the dosage form. Comparative in vitro dissolution studies were carried out in which 
optimized formula was compared with Innovator product (Nexavar). It was found that optimized 
formula has shown better dissolution profile than marketed product. 
Kinetic release Profile Modeling: 
 Regression coefficient (R2) values for different kinetic models for all formulations.  
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 Fig. 10.  Graphical representation of kinetic modelings for optimized formulation. 
It was found out that the optimized formulation was best explained by korsmeyer peppas Model             
(R2 = 0.896), then first order (R2 = 0.824) followed by Higuchi Model (R2 = 0.812) and Zero order 
(R2 = 0.697). This explains why the drug diffuses at a comparatively slower rate as the distance for 
diffusion increases, which is referred to as square root kinetics (or Higuchi’s Kinetics). Further, in 
the dissolution profile it was noted that the maximum release of the drug occurred at 15 minutes and 
followed the first order kinetics, where as in the graphical calculation, the regression co efficient for 
the korsmeyer pappas exhibited the maximum regression value. This may be due to the sink level 
saturation within 15 minutes. 
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Stability studies 
The optimized tablets from batch F3 were charged for stability studies at 400C and 75% RH. There 
was no change in physical appearance, color. Formulations were analyzed at the end of 3 months for 
general tablet properties like hardness, friability, drug content and dissolution studies. Tablets have 
shown no much deviation in hardness, friability values. And Average drug content of the tablets 
were found to be 99.5±0.4% of the labeled claim. In vitro dissolution profile showed that there was 
no significant change in the release rate of the drug from optimized tablets at the end of 6 months. 
 
 Table 28. Stability data for optimized tablets 
Characteristics 
 
Initial 1st  month 2nd month 3rd month 6th month 
Water content 1.826% 2.64% 2.77% 3.352% 3.3% 
Content 
uniformity 
99.8% 99.72% 99.7% 99.7% 99.68% 
% Friability 0.15 0.15 0.15 0.15 0.15 
Hardness 
(kg/cm2) 
8.9 8.9 8.9 8.9 8.9 
Disintegration 
time 
5min 20  
sec 
5 min 
20sec 
5min 25sec 5min 
27 sec 
5 min 
30sec 
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Table 29. Stability study data (Accelerated) of trial F – 03:  
S.No Parameters Specifications 
               Test Condition  
40 ± 20C & 75 ± 5% RH 
0 Day 1 2 3 
1 Description 
Pink coloured 
round shaped film 
coated tablet. 
Comply Comply Comply Comply 
2 Moisture content 
Not more than 
5.0% 1.826% 1.953% 2.297% 2.16% 
3 Assay NLS 90% &NMT 
110%of labeled 
amount of drug. 
99.6% 99.1% 100.8% 99.5% 
4 
 
 
 Related 
substances  
 by HPLC 
 
I.Unknown 
individual 
impurity 
maximum 
 
NMT 0.2% 
 
0.08% 0.008% 0.006% 0.023% 
II.Total 
impurity 
 
NMT 2% 
 
0.054% 0.055% 0.053% 0.090% 
5 Dissolution 
NLT 80% of 
labeled amount of 
sorafenib 
dissolved in 30 
min 
95.5% 85.9%   85.8% 81.8% 
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 Table 30. Stability study data (long term data) of trial F – 03: 
S.No Parameters Specifications 
Test Condition 
25 ± 20C & 60± 5% RH 
0 Day 1 2 3 
1 Description 
Pink coloured round 
shaped film coated 
tablet. 
Comply Comply Comply Comply 
2 Moisture content Not more than 5.0% 1.826% 1.947% 2.233% 2.218% 
3 Assay NLS 90% &NMT 
110%of labeled 
amount of drug. 
99.6% 100.0% 100.3% 99.2% 
4 
 
 
 Related 
substances  
 by HPLC 
 
I. 
Unknown 
individual 
 
NMT 0.2% 
0.008% 0.008% 0.007% 0.044% 
II.Total 
impurity 
 
NMT1.5% 
0.054% 0.059% 0.056% 0.099% 
5 Dissolution 
NLT 80% of labeled 
amount of sorafenib 
dissolved in 30 min 
95.5% 99.9%   99.5% 100.7% 
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 Table 31. Comparison of drug release profile of initial and stability batches 
Time Points Initial 
1st  
month 
2nd  
month 
3rd  
month 
6th month 
5 min 97.2% 96.5% 96.2% 95.8% 94.3% 
10 min 99.25% 97.6% 96.9%     96.1% 95.4% 
15 min 100.1% 98.3% 97.8% 97.5% 96.3% 
20 min 100.2% 99.1% 98.6% 98.3% 97.1% 
30 min 100.3% 99.9% 99.5% 98.9% 98% 
 
 Stability profile of Optimized formula 
 
 
 
 
 
 
 
 
 
Fig. 11. Comparison of dissolution profile for stability batches 
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Conclusion:  Stability studies for the optimized tablets was carried out  at different temperatures and 
relative humidity of 400C±20C, 75%±5% RH and 250 C ±20 C, 60%±5% RH for a period of six 
months. Tablets are evaluated for physical appearance, colour, hardness, friability, drug content and 
dissolution studies. Tablets have not shown any significant change during storage. Hence it was 
concluded that the optimized tablets have the good stability during their shelf life.                                 
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The objective of the present study was to design and develop a oral solid dosage form of low cost 
generic version Sorafenib tosylate film coated tablets with an aim to improve the bioavailability. 
Sorafenib tosylate is a antineoplastic agent having low bioavailability (25-49%), hence needed to 
be administered two times in a day to achieve therapeutic concentration level. 
Systematic studies were conducted using different polymers in different concentrations to 
prepare Sorafenib tosylate tablets. All the prepared systems were evaluated for the different 
parameters. Before the preparation of tablets, preformulation studies were conducted like drug- 
excipients stability studies to find out the interaction, micromeritic properties to assess 
flowability, compressibility and solubility. All the formulations gave good results for above 
preformulation studies. 
Formulated tablets gave satisfactory results for various physical tablet evaluation parameters like 
tablet dimensions, hardness, friability, weight variation and content uniformity and were found 
within the permissible range. 
Then prepared tablets were evaluated for in vitro drug release. In the present study, 
croscarmellose, crospovidone and sodium starch glycolate were used as disintegrants. 
Comparing these three disintegrants, it was found that the formulation containing croscarmellose 
has showed best dissolution profile. 
Drug release profiles are fitted to kinetic modelings like zero order, first order, Higuchi model 
and Korsemeyer Peppas models. In the dissolution profile, it was noted that the maximum 
release of the drug (95.8%) occurred at 15 minutes and followed the first order kinetics, where as 
in the graphical calculation, the regression coefficient for the Korsmeyer Peppas exhibited the 
maximum regression value. This may be due to the sink level saturation within 15 minutes. 
Stability studies were conducted for optimized formulation at 25°C with 60% RH and 40°C   
75% RH, and the formulation is found stable for all evaluation parameters. 
Finally it was concluded that: 
Formulation 1, which was prepared by direct compression method has shown poor flow 
properties and failed to achieve better dissolution profile. 
Chapter 8                                                            Summary and conclusion 
Department of Pharmaceutics Page 92 
 
Formulation 2 was prepared by the method of slugging has shown poor flow properties and 
sticking was observed during compression because of low fill weight, so the dissolution test was 
failed. 
Formulation 3 to 8 was prepared by the method of wet granulation with varying disintegrants 
like Croscarmellose, Crospovidone and Sodium starch glycolate in different concentrations. 
Formulation 3 prepared by using Croscarmellose in the concentration of 10% and SLS in the 
concentration of 2%, where tablets are film coated to increase the elegance and to give a good 
appeal, showed a better disintegration time and dissolution. 
To improve the dissolution of the drug, formulation 4 and 5 an attempt was made by using a 10% 
concentration of crospovidone and 10% concentration of sodium starch glycolte as disintegrants 
and they failed to show the disintegration time less than 30 min as per USP and they were also 
failed in stability. Hence formulation 6,7 and 8 was prepared by using Croscarmellose as 
disintegrant with 8%,12% and 14% concentrations. The disintegration time of formulation 6 was 
not under the specified limits, but formulations 7 and 8 showed a better dissolution profile. 
F9, F10, F11 formulation were prepared by using sodium lauryl sulphate in different 
concentrations of 1%, 3% and 4%. Among the three formulations F9 showed the drug release 
less than 70% which was not under the specified limits, where as F10 and F11 were found to 
exhibit a good dissolution profile.  The formulations which exhibited good dissolution profile 
were selected for comparison with the reference product. Comparing these formulations it was 
found that F3 was found to match the reference product. Hence stability studies were performed 
for this batch (F3) under accelerated and long term testing conditions.  The product was also 
analyzed for physical appearance, moisture content, assay, related substances and dissolution. 
The results obtained were found to be within the specified limits. 
The bigger scale confirmatory batch for the above said formulation (F12) was made and it is kept 
for 6 months accelerated stability studies and based on the result, a pilot scale will be executed. 
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Conclusion:  
Sorafenib tablets were prepared by direct compression, slugging and wet granulation method. 
From the results obtained it was found that the wet granulation method was found to be better 
when compared with the other two methods, since it exhibited a better dissolution profile 
matching the innovator product. Further, the drug release of the optimized formulation was 
found to be more than the reference product at the end of 30 minutes. 
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